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Résumé 
EIF4E, le facteur d’initiation de la traduction chez les eucaryotes est un oncogène puissant et 
qui se trouve induit dans plusieurs types de cancers, parmi lesquels les sous-types M4 et 
M5  de la  leucémie aiguë myéloblastique (LAM). EIF4E est régulé à plusieurs niveaux 
cependant, la régulation transcriptionnelle de ce gène est peu connue. Mes résultats montrent 
que EIF4E est une cible transcriptionnelle directe du facteur nucléaire «  kappa-light- chain-
enhancer of activated B cells » (NF-κB).Dans les cellules hématopoïétiques primaires et les 
lignées cellulaires, les niveaux de EIF4E sont induits par des inducteurs de NF-κB. En effet, 
l’inactivation pharmaceutique ou génétique de NF-κB réprime l’activation de EIF4E. En effet, 
suite à l’activation de NF-κB chez l’humain, le promoteur endogène de EIF4E recrute p65 
(RelA) et c-Rel aux sites évolutionnaires conservés  κB in vitro et in vivo en même temps que 
p300 ainsi que la forme phosphorylée de Pol II. De plus, p65 est sélectivement associé au 
promoteur de EIF4E dans les sous-types LAM M4/M5 mais non pas dans les autres sous-types 
LAM ou dans les cellules hématopoïétiques primaires normales. Ceci indique que ce 
processus représente un facteur essentiel qui détermine l’expression différentielle de  EIF4E 
dans la LAM. Les analyses de données d’expressions par séquençage de l’ARN provenant du 
« Cancer Genome Atlas  » (TCGA) suggèrent que les niveaux d’ARNm de EIF4E et RELA se 
trouvent augmentés dans les cas LAM à pronostic intermédiaire ou faible mais non pas dans 
les groupes cytogénétiquement favorables. De plus, des niveaux élevés d’ARNm de EIF4E et 
RELA sont significativement associés avec un taux de survie relativement bas chez les 
patients. En effet, les sites uniques κB se trouvant dans le promoteur de EIF4E recrutent le 
régulateur de transcription NF-κB p65 dans 47 nouvelles cibles prévues. Finalement, 6 
nouveaux facteurs de transcription potentiellement impliqués dans la régulation du gène 
EIF4E ont été prédits par des analyses de données ChIP-Seq provenant de l’encyclopédie des 
éléments d’ADN (ENCODE). Collectivement, ces résultats fournissent de nouveaux aperçus 
sur le control transcriptionnel de EIF4E et offrent une nouvelle base moléculaire pour sa 
dérégulation dans au moins un sous-groupe de spécimens de LAM. L’étude et la 
compréhension de ce niveau de régulation dans le contexte de spécimens de patients s’avère 
important pour le développement de nouvelles stratégies thérapeutiques ciblant l’expression 
du gène   EIF4E moyennant des inhibiteurs de NF-κB en combinaison avec la  ribavirine.   
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Abstract 
The eukaryotic translation initiation factor EIF4E is a powerful oncogene that is 
overexpressed in cancers, including the M4 and M5 subtypes of acute myeloid leukemia 
(AML). EIF4E is regulated at multiple levels; however not much is known about the 
transcriptional regulation of this gene. My findings show that the nuclear factor kappa-light- 
chain-enhancer of activated B cells (NF-κB) is a direct transcriptional regulator of EIF4E. 
EIF4E levels are induced in primary hematopoietic cells and in cell lines in response to NF-κB 
activating stimuli. Pharmacological and genetic inhibition of NF-κB suppresses EIF4E levels. 
NF-κB factors RelA (p65) and c-Rel are recruited to evolutionarily conserved κB sites in the 
EIF4E promoter in vitro and in vivo following NF-κB activation concurrent with the 
recruitment of p300 and phosphorylated Pol II. Furthermore, p65 is selectively associated with 
the EIF4E promoter in M4/M5 AML subtypes but not in other AML subtypes or normal 
primary hematopoietic cells and thus represents an underlying factor in determining the 
differential expression of EIF4E in AML. Analysis of gene expression RNA-Seq data from 
The Cancer Genome Atlas (TCGA) suggests that EIF4E and RELA mRNA levels are 
upregulated in intermediate and poor prognosis AML but not in the cytogenetically favorable 
group. Additionally, elevated EIF4E and RELA mRNA levels are significantly associated with 
worst patient survival outcome. Furthermore, 8 new putative NF-κB target genes that may be 
regulated with a pattern similar to EIF4E in poor prognosis AML were in silico predicted from 
Chip-Seq data. Finally, 6 new transcription factors that may be implicated in EIF4E gene 
regulation were predicted from the analysis of ChIP-Seq data from the encyclopedia of DNA 
elements (ENCODE). Collectively, these findings could offer novel insights into the 
transcriptional regulation of EIF4E and a novel molecular basis for its dysregulation in AML. 
Understanding this level of regulation within the context of patient specimens is important for 
the development of novel therapeutic strategies to target EIF4E gene expression with specific 
NF-κB inhibitors combined with ribavirin. 
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Chapter 1: Introduction 	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It is imperative that global rates of gene expression are strictly regulated to achieve optimal 
spatiotemporal RNA concentrations required to elicit a biological response1. Eukaryotic cells 
regulate gene expression through transcription, mRNA stability and post-transcriptional 
modifications, as well as protein synthesis (translation) and post-translational modifications. 
The RNA regulon model offers a blueprint in which cells regulate gene expression and protein 
synthesis. Cis-acting elements are positioned within the untranslated regions of transcripts 
known as untranslated sequence elements for regulation (USER) that recruit RNA binding 
proteins (RNPs) to modulate mRNA stability, export and translation1,2.  
 
Translational control is rapid and represents an important hallmark of cell development to 
modulate cell growth, proliferation and differentiation. Dysregulated expression and activity 
of components of the translation apparatus have been linked to cell transformation and 
carcinogenesis3. One key rate-limiting component, the eukaryotic initiation factor EIF4E, is 
upregulated in a plethora of cancers4,5. The transcriptional regulation of EIF4E and its 
dysregulation in acute myeloid leukemia (AML) is the focus of this thesis.  
 
1.1 Cap- Dependent Eukaryotic Translation Initiation 
Protein synthesis or mRNA translation is comprised of three distinct stages: initiation, 
elongation and termination3. The rate-limiting step in protein synthesis is translation initiation 
when the target mRNA is recognized by the translation machinery which catalyzes ribosomal 
assembly to commence protein synthesis3,6. Three mechanisms have been described so far for 
eukaryotic mRNA translational initiation7. These are (1) cap-dependent scanning8, (2) 
scanning-independent ribosomal shunting7 and (3) cap-independent scanning-independent 
internal ribosomal entry (IRE)9. In this thesis, I present my research on the initiation factor 
EIF4E, an integral component in the cap-dependent mode of translation initiation. 
1.1.1 A 7-methyl guanosine cap structure is required for cap-dependent translation 
initiation 
Following DNA transcription, the nascent pre-mRNA transcripts undergo a series of 
modifications including the amendment of a 7-methyl guanosine cap structure to the 5’ end of 
transcripts6. The process of mRNA cap methylation constitutes a key step that is essential for 
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gene expression. It involves two enzymatic reactions catalyzed by the RNA guanylyl 
transferase triphosphatase (RNGTT), that forms the 5’ guanylylated end on transcripts, and 
RNA methyl transferase (RNMT), which methylates the added 5’ guanosine.  It is has been 
demonstrated that elevating c-Myc expression promotes an increase in the proportion of 
capped transcripts, thus leading to increased rates of protein synthesis. c-Myc enhances 
capping by promoting RNA pol II phosphorylation as well as the upregulation of s-Adenosyl 
Homocysteine Hydrolase (SAHH)  which neutralizes s-Adenosyl Homocysteine (SAH), an 
inhibitory bi-product of methylation reactions10. 
 
The cap structure is essential for mRNA stability11, splicing12, nucleo-cytoplasmic export13 
and acts as a marker that interacts with the translation initiation machinery14. Evidence for cap 
requirement in translation initiation came from studies using protein synthesis-competent 
wheat germ extracts. In these studies, only capped reovirus RNAs formed an interaction with 
the 40S ribosomal subunit and were efficiently translated11,14. Addition of m7GDP cap analogs 
to the in vitro translation reaction or removal of the m7 cap structure from the viral transcripts 
diminished the translation of these RNAs15,  corroborating the importance of the cap structure 
in mRNA translation.  
 
In an attempt to decipher the mechanism through which the cap structure triggers mRNA 
translation, cap-binding complexes were identified and isolated using ribosomal washes from 
Artemia salina16 as well as from capped viral RNA studies. These complexes were originally 
referred to as cap binding proteins (CBP) I and II and are now known as eukaryotic translation 
initiation factors 4E (EIF4E) and 4F (EIF4F) respectively17,18. The EIF4E-cap interaction was 
displaced by cap analogs suggesting specificity. Furthermore, purified preparations of the 
25KDa EIF4E protein revealed an integral role in stimulating mRNA translation of only 
capped viral transcripts19. The EIF4F molecule was later shown to comprise EIF4E in complex 
with a 46KDa RNA helicase (EIF4A) and a 220KDa mRNA-ribosome bridging factor 
(EIF4G)20.  
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1.1.2 Molecular mechanism of cap-dependent translation initiation 
As illustrated in figure 1, the dissociation of the 80S ribosome marks the start of mRNA 
translation facilitated by EIF6, which binds the 60S ribosomal subunit as well as EIF3 and 
EIF1A that bind the 40S ribosome. The 40S subunit associated with EIF3 and EIF1A is loaded 
with EIF2 together with GTP and the initiator tRNA, Met-tRNA, forming the 43S pre-
initiation complex3,21. This complex is then recruited to the 5’ end of transcripts through its 
interaction with the EIF4F cap-binding complex.  
 
The EIF4F cap-binding complex is formed in three stages, first, EIF4E binds the 5’ capped 
end of transcripts; next, the scaffolding protein EIF4G binds EIF4E and recruits the 43S pre-
initiation complex to mRNA through its ability to interact with EIF3. The RNA helicase 
EIF4A and a “scanning” protein EIF4B are then recruited through EIF4G and are required to 
unwind the complex 5’ untranslated regions (5’UTR) and scan for the start codon positioned 
in the consensus “Kozak” initiator sequence3,8,21. The circularization of the complex is attained 
through the bridging properties of EIF4G that interacts with the polyA binding protein 
(PABP), which in turn binds the polyadenylated 3’ end of the transcripts. This subsequent 
association of the 43S pre-initiation complex and EIF4F results in the 48S complex3,21.  
 
The scanning properties of EIF4F allows the 48S complex to traverse the bound transcripts in 
a 5’ to 3’ fashion until the start codon (AUG) is located. Subsequently, the initiation factors 
are released in a process catalyzed by EIF5, a GTPase activating protein. The dissociation of 
these initiation factors allows the association of the 60S subunit and the commencement of 
translation elongation3. The association of 43S complex with mRNA through EIF4E 
constitutes the rate-limiting step in translation initiation3,6. The abundance and activity of the 
EIF4E protein is highly regulated in a multifactorial manner and will be discussed thoroughly 
in this chapter. 
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Figure 1. The mechanism of eukaryotic translation initiation. (A) Translation initiation 
commences with the dissociation of the 80S ribosomal subunit catalyzed by EIF1A, EIF3 and 
EIF6. The 40S subunit forms the 43S pre-initiation complex with EIF1A and EIF6 together 
with EIF2 and the Met initiator tRNA. (B) The 43S complex is recruited to the 5’ end of 
transcripts through its interaction with the EIF4F complex. The EIF4F complex is formed 
from three main proteins: the cap binding protein EIF4E, a scaffolding protein EIF4G and an 
RNA helicase EIF4A (coupled to the scanning factor EIF4B). The EIF4F complex can interact 
with the 43S complex through EIF3 and and recruits it to the bound transcripts forming the 
48S complex. Circularization is achieved through the interaction of EIF4G with the poly A 
binding protein (PABP). The 48S complex traverses the transcript in a 5’ to 3’ manner to 
locate the start codon. Translation initiation ends with the release of the initiation factors and 
the joining of the 60S ribosomal subunit.  
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1.2 Alternative Mechanisms for Translation Initiation 
Alternative mechanisms for translation initiation have been previously described and involve 
cap-independent strategies7. Some viral and cellular mRNAs are innately uncapped and are 
thus translated by a process involving internal initiation. These transcripts harbor an internal 
ribosome entry site (IRES), a structural element in the 5’UTR. This alternative mode of 
initiation involves direct recruitment of the initiation factors and ribosome complex to the 
IRES element independent of EIF4E through IRES trans acting factors (ITAFs)7,9,21. Under 
patho-physiological and stress conditions, cap-dependent translation is impaired; however, 
mRNA translation of a subset of transcripts is maintained with a translation initiation re-
programming in favor of IRES-mediated translation21. Translational profiling experiments 
performed under physiological and stress conditions such as, mitosis, differentiation and 
apoptosis as well as following heat shock and hypoxia, revealed that 10-15% of all mRNAs 
are translated potentially through an IRES-mediated process when cap-dependent translation is 
compromised21. This mechanism allows cells to adapt in response to various physiological and 
stress stimuli.  Interestingly, since this process still requires most of the translational 
machinery, several picornaviruses have evolved strategies to hijack the host’s translational 
machinery for viral protein synthesis through site-specific cleavage of EIF4G’s amino-
terminus compromising EIF4G-EIF4E interaction without altering its binding properties to 
other factors. This process diverts the host’s EIF4G protein from cap-dependent translation in 
favor of viral IRES-mediated protein synthesis22.  
 
Finally, a role for the cap binding complex Cbc1 in mRNA translation has been demonstrated. 
In yeast, global translation is suppressed in response to osmotic stress; however, mRNAs 
encoding stress protective proteins remain selectively translated to allow survival. This 
process was shown to be dependent on Cbc123. 
1.3 EIF4E Functions in mRNA Export and Translation 
1.3.1 Structure of the EIF4E gene, alternative splicing and homology 
The human eukaryotic initiation factor EIF4E gene spans more than 50 kilobase pairs (kbp) 
and is situated on chromosome 4. It is a functionally conserved gene encoded by 8 exons with 
three possible transcript variants illustrated in figure 2A. The most common transcript variant 
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1 (4749 bp) produces a 217 amino acid protein. Through alternative splicing, the longest 
transcript variant 2 (4842 bp) uses an alternative exon in the 3’ coding region producing a 248 
amino acid protein with an extended C-terminus. Transcript variant 3 (3406 bp) has a longer 
N-terminus producing a 237 amino acid protein by using an alternative exon in the 5’UTR and 
5’ coding region with a distinct initiation codon AUG. The alternatively spliced transcripts 2 
and 3 have been predicted from cDNA libraries; however, their expression and biological 
functions are yet to be investigated24.  
 
Interestingly, two EIF4E mammalian paralogues have been described and are referred to as 
EIF4E-2, also known as 4E-HP, and EIF4E-324,25. These proteins are distinct in their structure, 
function and expression pattern from the main ubiquitously expressed EIF4E-1 protein.  
EIF4E-2 is highly expressed in the testis whereas EIF4E-3 is mostly expressed in muscles, 
lung and spleen24. These paralogues have been shown to bind the 7-methyl cap26,27; however 
are, unlike EIF4E-1, incapable of functionally rescuing the growth-arrested phenotype in S. 
cerevisiae with a deletion in the cdc33 gene, an EIF4E orthologue, suggesting that EIF4E-2 
and EIF4E-3 fulfill distinct tissue-dependent functions24. In fact, studies have shown that 
EIF4E-2 and EIF4E-3 are not associated with EIF4G and are thus not part of the translation 
competent EIF4F complex. Furthermore, these proteins are incapable of binding known 
EIF4E-1 regulators such as the EIF4E binding protein 1(4E-BP1)26,27. These studies suggest 
that EIF4E paralogues may function as negative regulators of EIF4E-1 activity by competing 
for the same pool of capped transcripts and thus impede EIF4E-1 functions. The structure and 
function of the main EIF4E-1 protein will be further discussed and will be referred to as 
EIF4E.  
 
1.3.2 The EIF4E structure reveals a distinct mode for cap-recognition required in mRNA 
export and translation 
The EIF4E protein is of relatively small size at 25 KDa and is present as part of the EIF4F 
complex as well as in free form. The human and mouse cap-bound EIF4E structures have been 
elucidated with X-ray crystallography revealing a unique structure underlying EIF4E’s cap 
binding properties24.    
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Figure 2. The initiation factor EIF4E gene comprises 8 exons that codes for a cap-
binding protein with a unique structure. (A) Alternative splicing of the EIF4E gene 
produces three transcript variants, the most common being transcript variant 1 which produces 
a 217 amino acid protein. Transcript variant 2 uses an alternative exon in the 3’ coding region 
resulting in a 248 amino acid protein with a longer C-terminus. Transcript variant 3 has a 
longer N-terminus producing a 237 amino acid protein by using an alternative exon in the 5’ 
coding region. (B) Crystal structure of the mouse EIF4E bound the 7-methyl cap (blue) reveals 
a unique “cupped hand” structure composed of 8 anti-parallel beta strands supported by 3 
alpha helices. Cap binding involves aromatic pi-pi stacking and requires W56 (red) and W102 
(orange). (C) The 7-methyl cap (yellow) is nestled in a binding groove involving 7 amino 
acids: W56, W102, E103, W166, R157, K159 and K162 (see text for details). (D) The EIF4E 
dorsal surface binds protein partners that serve a regulatory purpose. Several key residues 
include H37, P38, L131, E132 and L135 (shown in red). Disruption of V69 (orange) and W73 
(beige) hinders EIF4E’s interaction with EIF4G and 4E-BPs. All cartoons were generated 
from the 1L8B structure, obtained from pdb.org, using pyMol. 
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The EIF4E protein consists of eight anti-parallel beta-sheets supported by three alpha-helices 
to form the palm and back of a cupped hand respectively28-30 as illustrated in figure 2B. 
Studies have shown that EIF4E recognizes the 7-methyl cap through intercalation between two 
aromatic residues W56 and W102, also known as π-π stacking31,32.  
 
Additional residues involved in cap recognition are highlighted in figure 2C and include a 
polar E103 that interacts with the nitrogen moiety of the cap, a W166 residue forming a 
hydrophobic interaction with the methyl group of the cap, and three positively charged 
residues R157, K159, K162 that interact with the phosphate backbone of the cap. Nuclear 
magnetic resonance (NMR) solution structure of the cap-free EIF4E form, apo-EIF4E, 
revealed that this factor remains structured; however, key structural variations in the cap-
binding pocket and the dorsal surface were noticed compared to the cap-bound EIF4E. 
Structural alterations in the S4-H4 loop distal to the cap binding pocket appears to be essential 
in regulating conformational changes in EIF4E following cap binding33.  
 
Structural studies with mouse EIF4E bound to EIF4G and 4E-BP1, an EIF4E regulator, 
revealed a requirement for the dorsal region in the EIF4E protein. Several amino acids (H37, 
P38, V69, W73, L131, E132 and L135) situated in the dorsal surface mediate EIF4E’s 
interaction with its binding partners and regulators34 (figure 2D). Disruption of two key 
phylogenetically conserved residues V69 and W73 hinders EIF4E’s interaction with EIF4G 
and 4E-BPs35,36. Interestingly, phylogenetic alignment studies of EIF4E revealed that only 
around 170 amino acids representing the EIF4E core are conserved in all eukaryotes. This 
region includes the amino acids involved in cap recognition as well as binding to EIF4E 
partners and regulators35,37. Accordingly, EIF4E is functionally conserved whereby 
mammalian EIF4E is capable of rescuing the growth-arrested phenotype in S. cerevisiae with 
a deletion in the cdc33 gene, an EIF4E orthologue, although it harbors only 30% sequence 
identity with its yeast counterpart38,39.   
 
Subcellular localization experiments revealed a dynamic nuclear and cytoplasmic localization 
for EIF4E. EIF4E functions at two levels: mRNA export and mRNA translation, both of which 
require cap recognition24 (figure 3). Transcripts that harbor a complex GC rich highly 
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structured 5’UTR have been shown to be translated more efficiently, in an EIF4F dependent 
fashion, than transcripts with short unstructured 5’UTRs40-42. These transcripts have been 
dubbed as EIF4E translationally sensitive targets and include genes involved in cell 
proliferation and survival such as PIM1, VEGF, MYC, ODC and many more41,43-45.  
 
The nuclear localization of EIF4E (up to 68%)46 suggests EIF4E nuclear functions. In fact, 
EIF4E has been shown to promote the export of transcripts containing a 50 nucleotide 4E-
sensitivity element (4E-SE) in their 3’UTR1,44,47,48. Transcripts containing a 4E-SE element are 
bound by the export factor LRPPRC that interacts with EIF4E resulting in a CRM1-dependant 
export; unlike bulk mRNA export which is TAP/NXF1 dependent48,49. EIF4E export targets 
are also of the pro-proliferative nature and include MYC, CCND1 (CyclinD1), ODC and many 
more44,47. Interestingly, EIF4E was also shown to reprogram the nuclear pore complex to 
enhance the export of its target genes. Specifically, the RanBP2 cytoplasmic fibrils reduce the 
release and recycling of export factors to the nucleus, thereby impeding EIF4E mediated 
export; EIF4E circumvents this inhibitory mechanism by indirectly reducing the levels of 
RanBP250. 
 
Eukaryotic cells organize the regulation of mRNA pools involved in the same biological 
process at the post-transcriptional level by altering the activities of RNPs interacting with 
these transcripts through USER sequences2. EIF4E functions to promote the nuclear export of 
its target genes and subsequently enhances the translation of the cytoplasmic EIF4E sensitive 
transcripts; these functions are independent of ongoing transcription and protein synthesis48. 
EIF4E export and translation targets are involved in cell proliferation and survival, 
accordingly, EIF4E is a central node of an RNA regulon that directs cell survival48. 
Importantly, not all EIF4E transcripts are sensitive at both export and translation levels24.   
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Figure 3: EIF4E functions at two levels: mRNA export and translation initiation. In the 
nucleus, EIF4E promotes the export of transcripts containing a unique 50 nucleotide element 
in their 3’ UTR referred to as the 4E sensitivity element (4E-SE). EIF4E export is CRM1 
dependent. In the cytoplasm, EIF4E enhances the translation of transcripts containing a 
complex highly structured 5’UTR. EIF4E export or translationally sensitive transcripts include 
genes involved in cell proliferation and survival (e.g. ODC, MYC, CCND1, VEGF, PIM1).  
EIF4E overexpression has been associated with cell transformation and tumor promotion 
owing to its proliferative and anti-apoptic program.  
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Finally, EIF4E’s pro-survival program endows oncogenic properties for this initiation factor; 
in fact, EIF4E is overexpressed in an estimated 30% of human cancers4,5.  
 
1.4 EIF4E regulation is multifaceted with distinct levels of control 
EIF4E expression and activity are regulated at multiple levels through transcription, mRNA 
stability, protein interactions as well as post-translational modifications. These distinct modes 
of regulation are illustrated in figures 4 and 5. Dysregulation in EIF4E control modules have 
been linked to malignant transformation6.  
 
1.4.1 A c-Myc centric view for EIF4E transcriptional control 
The identification and cloning of the EIF4E promoter was achieved through screening human 
genomic DNA libraries using 5’c-DNA probes corresponding to EIF4E exons51. The 
transcription start site (TSS) of EIF4E was mapped with RNase protection assays51,52. The 
EIF4E promoter lacks a TATA box but harbors a polypyrimidine tract at position -25 distal to 
the TSS known as the EIF4E basal element (4EBE)53. This element binds the heteronuclear 
ribonuclear protein K (hnRNPK) that recruits the TATA binding protein (TBP) and 
consequently the basal transcription machinery to the EIF4E promoter53,54. Studies of the 
EIF4E promoter revealed multiple E-box elements that were shown to bind c-Myc and 
transactivate the EIF4E gene51 as seen in figure 4. The tumor suppressor p53 was shown to 
repress EIF4E through luciferase reporter assays (LRA) possibly through sequestering c-Myc 
and hindering its interaction with the promoter55. In addition, the sonic hedgehog pathway was 
also shown to upregulate EIF4E in neural cells through Myc56. Accordingly, for the past 16 
years EIF4E transcriptional regulation has been solely the purview of Myc; however, EIF4E 
transcript is still inducible in Myc null fibroblasts following serum stimulation57 suggesting 
that other mechanisms are involved in EIF4E transcription. Consistent with this idea, a recent 
report suggests that EIF4E is also a C/EBP target58. In fact, the EIF4E promoter is enriched 
with binding sites for a plethora of transcription regulators including NF-κB, STAT, PU.1, 
PAX, NFAT, GATA, SP1 and many more59. This doctoral thesis focuses on the transcriptional 
regulation of EIF4E through NF-κB and its dysregulation in AML.  
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Figure 4. The Myc-centric view depicting EIF4E transcriptional control. The EIF4E 
promoter harbors multiple E-box elements that recruit c-Myc and upregulate EIF4E 
expression. The tumor suppressor p53 represses EIF4E expression by sequestering Myc and 
hindering its interaction with the promoter. The sonic hedgehog (SHH) pathway induces a 
Myc-dependent EIF4E expression in neuronal cells. These pathways illustrate Myc-centric 
mechanisms for the transcriptional regulation of EIF4E.   
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1.4.2 The stability of EIF4E mRNA is regulated by HuR and AUF1 
Three conserved AU rich elements (AREs) have been identified in the 3’UTR of EIF4E. 
These elements direct HuR binding to stabilize the EIF4E transcript. On the other hand, a 
competing destabilizing protein, p42 AUF1, was shown to reduce EIF4E transcript stability. 
Furthermore, HuR is upregulated in cancer cells with elevated EIF4E expression and depletion 
of HuR in cancer cells results in EIF4E downregulation60. Thus EIF4E expression is also 
modulated through post-transcriptional events independent of EIF4E transcript levels (figure 
5A). 
 
1.4.3 EIF4E activity is modulated by protein interactions with a multitude of regulators 
Another mode of EIF4E regulation involves its interaction with binding proteins that confer an 
activating or inhibitory effect6 (figure 5B). Experiments conducted with Far-Western 
hybridization led to the isolation of two small proteins that interact with EIF4E and were 
referred to as EIF4E binding proteins 4E-BP1 and 4E-BP261. Many proteins that bind EIF4E 
share the following small conserved amino acid motif YXXXXLϕ, where X is any residue and 
ϕ is a hydrophobic amino acid62. Accordingly, 4E-BPs compete with EIF4G to bind EIF4E 
and prohibit its access to the translational apparatus. In fact, 4E-BPs enhance the cap binding 
affinity in EIF4E thereby sequestering the bound EIF4E-mRNA complex to inhibit 
translation61,63. The dual cytoplasmic and nuclear localization of 4E-BPs suggests that these 
binding proteins can alter both EIF4E export and translation activities64. Importantly, 4E-BPs 
are regulated by phosphorylation through the mammalian target of rapamycin (mTOR); this 
reduces the interaction with EIF4E and increases translational activity65.  
 
Interestingly, mice lacking 4E-BPs were not more prone to developing cancers than controls66-
68 suggesting a redundancy in EIF4E regulators.  A multitude of proteins have been identified 
that contain the consensus EIF4E binding motif including more than 200 homeodomain 
proteins; these proteins can act as positive and/or negative regulators of EIF4E activity24. The 
PRH/Hex homeodomain protein is a negative regulator of EIF4E’s nuclear export 
functions69,70 whereas HoxA9 was shown to promote both EIF4E export and translation 
functions71.    
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Figure 5. EIF4E is regulated at multiple levels through transcript stability, protein 
interactions and post-translational modifications. (A) The EIF4E mRNA harbors 3 AU rich 
elements (AREs) in the 3’UTR that bind HuR and AUF1. EIF4E transcript stability is 
enhanced by HuR and reduced with AUF1. (B) EIF4E activity is modulated by multiple 
protein-protein interactions. HoxA9 promotes the export and translation functions of EIF4E, 
whereas PRH and PML inhibit EIF4E-mediated export. On the other hand, 4E-BPs can inhibit 
both EIF4E export and translation activities. (C) EIF4E activity is also regulated through post-
translational modifications. EIF4E sumoylation and phosphorylation enhance its translation 
functions. Ubiquitination of the EIF4E protein promotes its proteasomal-mediated 
degradation.   
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Additional homeodomain proteins shown to alter EIF4E activity include Otx, Engrailed 2, 
Emx2, Bicoid and Hox1172.  
 
Furthermore, two additional distinct protein families have been shown to interact with EIF4E 
and regulate its activity; they lack the YXXXXLϕ motif and include the RING domain 
containing proteins as well as the virus protein linked to the genome (VPg).  Promyelocytic 
leukemia (PML) and arenaviral Z proteins are RING domain containing proteins that impede 
EIF4E activity by reducing its affinity to the 7-methyl cap (~100 fold)24. Nuclear PML was 
shown to impede EIF4E’s mRNA export function73.  The potyviral VPg was shown to form a 
complex with EIF4E and reduces its affinity for the mRNA cap74. 
 
The regulation of EIF4E through binding partners is thus multifaceted24 involving an 
abundance of proteins expressed at various stages of the cell cycle and development to ensure 
optimal levels of EIF4E activity.  
 
1.4.4 EIF4E activity is modulated through post-translational modifications 
A fourth level of EIF4E regulation involves post-translational modifications of the EIF4E 
protein6 including phosphorylation, ubiquitylation and sumoylation (figure 5C). The 
phosphorylation status of EIF4E reflects the translation rate and growth state of the cell6. The 
stress and cytokine activated p38 mitogen activated protein kinase (p38 MAPK) pathway 
converges at two EIF4E kinases, Mnk1 and Mnk2, to phosphorylate EIF4E at residue S20975-
77. EIF4E phosphorylation enhances its export function and cell transformation capacity78. 
Furthermore, EIF4E could also be modified by ubiquitylation and SUMO1 conjugation79-81. 
 
This described multifactorial regulation of EIF4E ensures that ideal levels of EIF4E protein 
and activity are maintained to achieve an appropriate biological effect in response to 
physiological stimuli. Aberrant regulation of EIF4E expression and/or activity has been linked 
to malignancies as well as cell transformation.  
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1.5 EIF4E is Overexpressed in approximately 30% of Human Cancers and is a Plausible 
Candidate for Clinical Targeting 
EIF4E target genes at the export and translation levels impart a proliferative effect48. In fact, 
microinjection of EIF4E in quiescent fibroblasts promotes DNA synthesis82. In addition, 
EIF4E overexpression decreases cell cycle transit time in HeLa cells, whereas downregulation 
of EIF4E using anti-sense methods increases transit time in a dose-dependent fashion83. These 
studies demonstrated a role of EIF4E in supporting cell cycle progression and cell 
transformation6. Furthermore, anti-apoptic functions have also been described for EIF4E 
whereby overexpression in NIH3T3 cells blocks apoptosis following serum deprivation84. 
Additionally, EIF4E overexpression impedes Myc-driven apoptosis84. Taken together, these 
studies highlight EIF4E’s pro-survival properties. EIF4E is overexpressed in a multitude of 
cancers including hematopoietic malignancies and solid tumors4,5.  
 
EIF4E overexpression is underlined by several factors and is correlated with poor prognosis. 
EIF4E overexpression at the RNA and protein levels has been described in epithelial cancers 
including breast, colon, prostate, lung, cervix and squamous head and neck carcinoma. EIF4E 
gene amplification has also been described in head and neck as well as breast carcinomas. 
Hematopoietic cancers with elevated EIF4E levels include AML and Hodgkin and non-
Hodgkin lymphomas4. In this thesis, I present a new mechanism underlying the dysregulation 
of EIF4E in AML. A brief overview on AML and its classification systems will be covered in 
this chapter.  
 
Increased levels of EIF4E drive cell transformation and oncogenesis, accordingly, EIF4E 
represented a plausible candidate for clinical targeting85. Several preclinical and clinical 
methods have been described including synthetic peptides, anti-sense oligos, suicide gene 
therapy as well as a cap mimetic. Through a high throughput fluorescence polarization binding 
screen, the 4EGI-1 synthetic peptide was identified. This peptide inhibits the association of 
EIF4E with the EIF4G and blocks the formation of an active EIF4F complex. 4EGI-1 was 
shown to posses preferential activity in transformed cells and reduces the expression of MYC 
and BCL2L1 (BclXL), both of which are EIF4E targets86. Small molecule analogs for 4EGI-1 
have been described to target EIF4E in T-cell leukemia and non-small-cell lung cancer cells85. 
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Anti-sense oligonucleotides targeting EIF4E have been described in breast, prostate and head 
and neck carcinoma xenograft models87-89. In addition, a suicide gene therapy strategy has 
effectively targeted EIF4E in a head and neck carcinoma mouse xenograft model by fusing a 
complex structured 5’UTR upstream of the toxic gene encoding thymidine kinase TK, thereby 
promoting its expression in cells with upregulated EIF4E90. Furthermore, a novel strategy in 
epithelial ovarian cancer with upregulated gonadotropin releasing hormone (GnRH) receptor 
has also been described by fusing the EIF4E negative regulator 4EBP1 to agonists of the 
GnRH receptor to inhibit EIF4E activity in those cells91.  
 
Finally, an effective EIF4E targeting strategy using a 7-methyl cap mimetic, ribavirin, has 
been demonstrated in AML92,93, breast cancer94 as well as head and neck carcinoma mouse 
xenograft model93. Ribavirin, an antiviral drug established in hepatitis C treatment, is 
structurally similar to the 7-methyl cap and was shown to physically interact with EIF4E93,95,96 
to impede its oncogenic functions in phase II clinical trial of poor prognosis AML, leading to 
clinical response with no adverse drug-related side effects92. This provided a novel clinical 
approach to target mRNA translation in cancers with elevated EIF4E. Importantly, ribavirin is 
the only EIF4E inhibitor to date that has provided promising clinical outcomes. Furthermore, 
similar exciting findings have been observed in AML patients treated with Ribavirin plus low 
dose cytarabine (Ara-C) with remission up to two years (Assouline et al. In press). Finally, 
Ribavirin resistance has been observed in AML patients and has been attributed to a GLI1 
driven UGT1A-dependent glucuronidation of ribavirin. In this same study, ribavirin resistance 
was overcome by genetic or pharmacological inhibition of GLI1, suggesting a novel strategy 
to overcome ribavirin resistance in the treated patients97. 
 
 1.6 Acute Myeloid Leukemia: A Hematopoietic Malignancy with Aberrant EIF4E 
Expression and Activity 
Acute myeloid leukemia is a hematological malignancy of the myeloid lineage of blood cells; 
this malignancy affects the immature myeloid population of cells (myeloblasts) that expand at 
the expense of normal cells98. AML is a disease of older adults (> 60 years of age) with a 
median age at diagnosis of 67 years. The yearly incidence of new AML diagnoses in the USA 
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is 17.6/100,000 for individuals > 65 years of age, compared to 1.8/100,000 for individuals < 
65 years (2008 statistics)99. The average 5-year overall survival (OS) rates, in patients 
receiving therapy, range from 5–15% in older adults and approach 30% in younger adults with 
AML99. The French-American-British classification (FAB) has classified AML into 9 distinct 
groups based on of the type of cell from which the leukemia has developed as well as the 
degree of maturity. The groups are: M0 (minimally differentiated), M1 (no maturation), M2 
(granulocytic maturation), M3 (promyelocytic leukemia), M4 (myelomonocytic), M5a 
(monoblastic), M5b (monocytic), M6 (erythrocytic) and M7 (megakaryocytic)98,100. 
 
Several epigenetic and genetic anomalies underscore AML blasts progression. Epigenetic and/ 
or cytogenetic aberrations may result in the overexpression or the formation of fusion genes 
resulting in a blockade of myeloid differentiation and the formation of immature myeloblasts. 
Additionally, aberrant constitutive activation of cell receptors (e.g. Flt3, c-kit) confers a 
proliferative advantage to blast cells98. Notably, many AML cases are characterized by a 
normal karyotype.  
 
1.6.1 Cytogenetic and Molecular classification of AML to predict patient prognosis 
The four decades old FAB AML classification system has been subject to criticism, revisions 
and re-evaluations since the techniques required in classifying AML samples into FAB groups 
are very descriptive and rely on cell morphological features as well as simple cytochemical 
assays101. Accordingly, the World Health Organization (WHO) classifies AML into three 
clinical prognosis groups: favorable, intermediate and poor prognosis. The criteria required in 
this diagnostic classification are based on clinical data (patient history), cytogenetic analysis, 
immunophenotyping and biological features. This system aimed at offering a clinically 
relevant approach to determine prognostic parameters and plan more effective treatment 
regimen102,103.  
 
The advent of sequencing technologies has improved the WHO cytogenetic prognostic model 
through establishing molecular markers in all cytogenetic AML groups. This approach 
allowed for the classification of 5 prognostic subgroups with significant differences in OS thus 
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Table 1. Classification of AML into five clinical prognosis groups based on the underlying 
cytogenetic and molecular aberrations. The five distinct AML prognosis groups are shown 
with the underlying anomalies and frequency of occurrence. The 3-year overall survival (%) as 
well as the median survival rates for patients harboring the outlined anomalies are presented 
when applicable. NA, Not Applicable. Adapted from Grossmann et al.104  
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leading to a model based on molecular markers that is more comprehensive than standalone 
cytogenetics104. A summary of this prognostic classification system with the underlying 
cytogenetic and molecular aberrations and the associated OS rates is summarized in Table 1. 
 
1.6.2 EIF4E is overexpressed in poor prognosis AML 
A striking trend for EIF4E overexpression was observed in M4/M5 poor prognosis primary 
AML specimens but not in most M1/M2 specimens, with more than 100 samples tested70. The 
EIF4E export function is also augmented in M4/M5 AML; these samples show a predominant 
EIF4E nuclear accumulation. The nuclear function of EIF4E was shown to contribute to 
leukemogenesis by enhancing the export of target genes imparting a pro-proliferative and anti-
differentiation program70.  Molecular targeting of EIF4E with ribavirin (1µM) in M4/M5 
primary AML specimens resulted in an EIF4E relocalization from the nucleus to the 
cytoplasm and inhibited EIF4E export functions leading to growth suppression. On the other 
hand, M1/M2 AML specimens with normal EIF4E levels were inhibited at a much higher 
concentration; additionally, M1 AML specimens with high EIF4E were also affected93. 
Accordingly, targeting EIF4E with ribavirin in poor prognosis AML patients led to clinical 
response92. These findings suggest that AML cells overexpressing EIF4E evolved an EIF4E 
dependency for proliferation and survival and thus have an oncogene addiction to EIF4E92,93.  
 
The molecular underpinnings for EIF4E’s differential regulation in AML will be discussed in 
chapter 2. Furthermore, the expression pattern of this oncogene has not been investigated in 
clinical prognosis AML groups and accordingly, this notion will be discussed in chapter 3.  
 
1.7 Disruption of NF-κB activity in AML alters EIF4E expression and localization 
The nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) pathway is 
constitutively activated in primary leukemia specimens105. The link between NF-κB and 
EIF4E came from experiments performed in M5 primary AML and bc-CML (blast crisis 
Chronic Myelogenous Leukemia) specimens. In these cells, genetic NF-κB disruption with a 
super repressor (IκB-SR) resulted in a downregulation of EIF4E transcript and protein70. 
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Furthermore, NF-κB suppression led to the re-organization of EIF4E nuclear bodies and its co-
localization with PRH70, a negative regulator of EIF4E activity69.  
 
These findings suggest that EIF4E expression and activity are regulated through the NF-κB 
pathway; however, the molecular mechanism underlying this control was not further 
investigated. The transcriptional regulation of EIF4E through NF-κB and its dysregulation in 
AML is the focus of this thesis.  
 
1.8 An Overview of the NF-κB Pathway and its Dysregulation in AML 
The NF-κB factors belong to a family of ubiquitous and inducible regulators first discovered 
by Sen and Baltimore in 1986 in the nuclei of activated B-cells106. They are evolutionary 
conserved from Cnidarians to humans but are absent in yeast and C. elegans, suggesting that 
they might have been lost during evolution107. They have been implicated in development as 
well as host defense and immune functions. Aberrations in this pathway have been linked to a 
variety of human diseases including arthritis, asthma, atherosclerosis, AIDS, inflammation as 
well as malignant transformation and oncogenesis108. 
 
1.8.1 NF-κB transcription factors 
The mammalian NF-κB pathway is comprised of five distinct transcription regulators 
classified into two groups. The first group includes NF-κB1 (p105/p50) and NF-κB2 
(p100/p52), whereas the second group includes RelA (p65), RelB and c-Rel. These proteins 
share a conserved 300 amino acid Rel homology N-terminus domain required for dimerization 
and DNA binding. NF-κB transcription factors exist as homo- or heterodimers and bind 10 bp 
cognate DNA sequences known as κB sites following the consensus motif 5’-
GGGRNYYYCC-3’ where R is a purine, Y is a pyrimidine and N is any nucleotide. Members 
of the first group are synthesized as precursor proteins (p105 and p100) containing ankyrin 
repeats that shield the nuclear localization signal; accordingly, these proteins must undergo 
limited proteolysis to yield the active subunits (p50 and p52). Members of the second NF-κB 
group share a C-terminus transactivation domain to regulate target gene expression108.  
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In resting cells, NF-κB transcription factors reside in the cytoplasm and are kept inactive by 
the IκB family of inhibitors. Signals that elicit an NF-κB response trigger a cascade leading to 
the phosphorylation and degradation of the IκB-α inhibitor thus liberating NF-κB dimers that 
translocate to the nucleus and modulate gene transcription107. 
  
NF-κB gene deletion studies suggested a role for these transcription regulators in development 
and immune response108. NFκB1 (p50) is critical for the survival of non-activated B-cells109. 
NFκB2 (p52) is required for antigen presentation in dendritic cells and macrophages as well as 
the maintenance of lymph node and splenic architecture110. RELA (p65) knockouts are 
embryonic lethal due to defective fetal liver development111. Accordingly, p65 NF-κB has 
been implicated in cell survival and has been shown to promote induced lymphocyte 
proliferation and isotype switching112. The c-Rel NF-κB factor is important for B-cell 
proliferation in response to immunogens as well as cytokine production in T-cells and 
macrophages113. RelB has been shown to cross talk with the aryl hydrocarbon receptor (AhR) 
pathway and mediate an inflammatory response114.  
 
1.8.2 NF-κB signaling pathways 
The NF-κB axis is activated by diverse stimuli and physiological conditions including 
cytokines and growth factors, viruses and bacteria and their products, carcinogens, tumor 
promoters, reactive oxygen species, stress as well as apoptosis inducers108. Two major NF-κB 
signal transduction pathways have been described: canonical and non-canonical, these are 
illustrated in figure 6.  
 
The canonical pathway is the classic NF-κB activation pathway (figure 6A) that is triggered by 
ligand binding to cell surface receptors such as the tumor necrosis factor receptor, cytokine 
receptor, toll-like receptor as well as B- and T-cell receptors107. Receptor activation recruits 
scaffolding proteins (e.g. RIP, TRAF, TRADD, MyD88) and converges on an NF-κB 
activating module known as the IκB Kinase complex (IKK)115. The IKK complex is composed 
of three subunits: two catalytic subunits (IKKα and IKKβ) as well as a regulatory subunit 
IKKγ, also known as the NF-κB essential modulator (NEMO)108. The recruitment and  
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Figure 6. The NF-κB signaling pathways involve two main transduction modules: 
canonical and non-canonical. (A) The canonical pathway is triggered through the TNF, Toll-
like, cytokine, B- and T-cell receptors to promote the activation of the NF-κB proteins p50, 
RelA (p65) and c-Rel. Activation leads to rapid recruitment of scaffolding proteins (e.g. RIP, 
TRAF, TRADD, MyD88). The kinase TAB/TAK phosphorylates and activates the IKK 
complex. Phosphorylation of the NF-κB inhibitor IκB-α through IKKβ promotes its 
degradation and subsequent translocation of NF-κB transcription factors the nucleus to induce 
a proliferative gene expression program. The phorbol ester PMA induces NF-κB through 
PKC. (B) The alternative non-canonical NF-κB activation pathway is triggered by ligands 
acting through the lymphotoxin receptor as well as the TNF receptors, CD40 and BAFFR. In 
the absence of a ligand, the NF-κB inducing kinase (NIK) is ubiquitinated and degraded. 
Following stimulation, NIK ubiquitination is arrested leading to its accumulation and the 
subsequent activation of IKKα. The NF-κB proteins affected in this pathway are p100 and 
RelB. P100 undergoes phosphorylation through IKKα, which promotes its limited proteolysis 
into active p52. Consequently, p52/RelB complexes translocate to the nucleus to promote the 
expression of genes involved in lymphoid organogenesis and adaptive immunity. 
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activation of the IKK complex often involves K63-linked ubiquitination of the scaffolding 
proteins as well as the NEMO subunit by the Ubc13/Uev1 and the HOIP/HOIL-1L ubiquitin 
ligases. Two deubiquitinases, A20 and CYLD, have been shown to negatively regulate NF-κB 
activation by reversing the activating K63-linked ubiquitination of NEMO and the recruiting 
scaffolding proteins115.  
 
The ubiquitinated scaffolding proteins would then serve as a platform to recruit the activating 
kinase complex composed of the transforming growth factor β activated protein kinase 1 
(TAK1) and the TAK1 binding protein (TAB). The TAB/TAK1 complex phosphorylates and 
activates the IKK complex through IKKβ115. Activated IKKβ then phosphorylates the NF-κB 
inhibitor IκB-α at S32 and S36. Subsequently, the phosphorylated IκB-α undergoes K48-
linked ubiquitination at K21 and K22 by the SCF-βTrCP ubiquitin ligase leading to 
degradation in the 26S proteasome108. IκB-α degradation allows NF-κB dimers containing NF-
κB1 (p50), RelA (p65) and c-Rel to translocate to the nucleus and modulate target gene 
expression115.  Furthermore, NF-κB activation independent of IκB-α degradation has been 
described in response to stress signals including hypoxia and exposure to ionizing irradiation 
as well as in response to erythropoietin and the epidermal growth factor (EGF).  These signals 
promote NF-κB activation through Y42 phosphorylation of IκB-α without its degradation108.  
 
Small cell permeable molecules including the tumor promoter phorbol ester, PMA, can also 
trigger the canonical NF-κB pathway106. PMA binds and activates protein kinase C, PKC116, 
which in turn activates IKK through the mucosa associated lymphoid tissue lymphoma 
complex, CARMA1/Bcl10/MALT1117,118. Importantly, PMA is a pleiotropic agent that 
triggers additional signaling pathways and thus proper experimental design must be 
implemented when studying PMA-induced NF-κB activation; for instance, coupling PMA 
treatment with NF-κB inhibitors.  
 
The alternative non-canonical NF-κB activation pathway (figure 6B) is required during B- and 
T-cell development. This pathway converges on NF-κB2/RelB and is triggered by specific 
receptor signals including lymphotoxin (LTβ), B-cell activating factor (BAFF) and CD40107. 
In unstimulated cells, the NF-κB inducing kinase (NIK) is kept in an inactive state through 
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K48-linked ubiquitination and degradation. However, in response to signals triggering the 
alternative NF-κB pathway, NIK accumulates and is activated through auto-phosphorylation. 
Activated NIK phosphorylates IKKα homodimers, which in turn phosphorylates NF-κB2 
(p100) leading to proteasome-mediated limited proteolysis of p100 into active p52. RelB/p52 
heterodimers are formed and undergo nuclear import to promote a gene expression program 
underlying adaptive immunity and lymphoid organogenesis115.  
 
1.8.3 NF-κB factors exert a bimodal transcriptional activity 
NF-κB factors exert their transcriptional activity through a transactivation domain (TAD) to 
modulate diverse gene expression programs. The NF-κB proteins p50 and p52 lack a TAD and 
thus must exist in complex with p65, c-Rel and RelB. In fact, homodimers formed from p50 or 
p52 subunits act as repressors of gene transcription119. The TAD of NF-κB proteins interact 
with different components of the basal transcriptional machinery including the TATA binding 
protein (TBP) and transcription factor IIB (TFIIB)119. NF-κB factors regulate gene expression 
through histone modification and chromatin remodeling as well as through regulation of 
transcription elongation. The p300 histone acetyltransferase (HAT) as well as histone 
deacetylases (HDACs) are recruited by NF-κB factors to exert positive and negative effects on 
gene expression respectively119. Furthermore, NF-κB proteins modulate transcription by 
recruiting regulators of transcriptional elongation: the DRB sensitivity-inducing factor (DSIF), 
the negative regulator of transcription elongation (NELF) and the positive regulator of 
transcriptional elongation (pTEFb). Recruitment of DSIF and NELF negatively modulates 
RNA polymerase (RNAP); on the other hand, pTEFb recruitment promotes the 
phosphorylation of the RNAP C-terminal domain and subsequently transcriptional 
activation120,121. This differential mode of regulation through elongation factors is largely 
dependent on the core promoter type in target genes121.  
 
NF-κB transcription factors modulate gene expression by acting as activators or repressors; 
this bimodal transcriptional activity is dependent on the inducing stimulus and physiologic 
context, post-translational modifications of NF-κB factors as well as the interaction with 
nuclear non-Rel proteins that modulate the selectivity of the NF-κB response119,122.   
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NF-κB signaling is triggered by a variety of stimuli under distinct physiologic contexts 
ranging from growth promoting stimuli to stress, DNA damaging agents and death 
receptors119. Accordingly, two facets of NF-κB mediated transcriptional regulation are 
invoked in response to divergent stimuli. Growth promoting agents such as EGF harness the 
proliferative “face” of NF-κB activity which upregulates the anti-apoptic genes MCL1, BCL2 
and BCL2L1 (BclXL) as well as repress cell death by downregulating the pro-apoptic genes 
TNFRSF10B (DR5), FAS, and FASL. On the other hand, exposure to stress causing stimuli 
utilizes a different facet of NF-κB activity, which increases the expression of pro-apoptic 
genes and downregulates the anti-apoptic program. These divergent facets of NF-κB activity 
involve NF-κB mediated chromatin remodeling through the histone modifying enzymes p300 
and HDACs119. Furthermore, some NF-κB target gene promoters are pre-bound by NF-κB 
proteins, which are coordinately replaced by other NF-κB containing complexes in response to 
an activating stimulus123. Thus, NF-κB target genes can be positively and negatively regulated 
dependent on the physiologic context.  
 
NF-κB transcriptional activity is essentially dependent on post-translational modifications 
including phosphorylation, ubiquitination, acetylation, nitrosylation, prolyl isomerization and 
mono-methylation. These modification patterns act as “barcodes” for dictating NF-κB 
transcriptional activity. NF-κB p65 phosphorylation occurs at multiple serine and threonine 
residues including S468, S536, S276, S311, T505 and T254. These phosphorylation patterns 
modulate p65 activity and can promote either transactivation or repression depending on the 
cell cycle and stimulus122,124,125. For instance, phosphorylated p65 upregulates the expression 
of the matrix metalloproteinase genes MMP3 and MMP13; on the other hand, the same 
phosphorylation pattern represses the expression of the adhesion genes ICAM and VCAM125. 
Phosphorylation patterns that impart a transactivating potential promote the recruitment of 
p300; conversely, patterns that elicit a repressive effect promote the recruitment of HDACs. 
NF-κB p65 is also acetylated at five key lysine residues. Acetylation at residues K218, K221 
and K310 enhances DNA binding activity and transactivation; on the other hand, acetylation at 
K122 and K123 impairs p65-mediated transactivation119. A summary of the post-translational 
modifications of NF-κB subunits is shown in table 2. 
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Recent studies suggest that specific nuclear signaling is integral in regulating NF-κB activity. 
This involves the interaction with non-Rel (i.e. non- NF-κB) nuclear proteins that selectively 
modulate DNA recognition and transactivation of NF-κB factors. Non-Rel proteins have been 
shown to either positively or negatively regulate NF-κB activity. Positive regulators include 
RPS3, AKT1, CD40, CD30, BAFFR, AKIRINs, AEG1 and AKIP1. These non-Rel proteins 
enhance NF-κB activity by promoting positive NF-κB post-translational modifications as well 
as the recruitment of p300 HAT. On the other hand, non-Rel negative regulators of NF-κB 
activity include CHFR, ING4, SIRT1/6, NURR1, PDLIM2 and COMMD1, which favor the 
recruitment of HDACs and promote gene repression of NF-κB targets.  Furthermore, non-Rel 
nuclear proteins modulate the selectivity and affinity of NF-κB factors to κB sites in the 
genome122.  
 
1.8.4 NF-κB is constitutively activated in cancer 
Genetic and cytogenetic anomalies as well as aberrations in the tissue microenvironment 
underlie carcinogenesis. NF-κB is constitutively activated in tumors with persistent nuclear 
localization. This constitutive activity is triggered by the tumor microenvironment (e.g. stress, 
pH), augmented signaling cascades that induce NF-κB as well as alterations in NF-κB protein 
expression or dysregulation of NF-κB inhibitors. Alterations in NF-κB proteins occur in a 
variety of cancers as a result of gene amplification as well as chromosomal rearrangement. 
Increased expression of NF-κB factors contributes to their constitutive activity by crowding 
the inhibitor IκB-α and thus spontaneously undergoes nuclear translocation in the absence of a 
stimulus.  Inactivating mutations in the inhibitor IκB-α has also been linked to constitutive 
NF-κB activation. Cancers with aberrant NF-κB regulation include AML, Hodgkin’s 
lymphoma, B- and T-cell leukemias and lymphomas, breast, liver, prostate, thyroid, bladder, 
ovarian, colon and lung cancer108. In AML, the NF-κB factor p65 is upregulated owing to a 
gene amplification as a result of a trisomy in chromosome 11102. Furthermore, NF-κB is 
constitutively activated in all AML subtypes. Interestingly, aberrant EIF4E and NFκB 
expression levels overlap in a multitude of cancers including AML. 
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Constitutive NF-κB activity promotes cell transformation, tumor initiation and promotion as 
well as angiogenesis, cell invasion and metastasis. This is achieved through NF-κB mediated 
upregulation of pro-proliferative and anti-apoptic gene expression programs. Increased cell 
survival is achieved by upregulating the anti-apoptic genes BCL2, BIRC (cIAP), SOD and 
TRAF. In addition, the tumor microenvironment is maintained by NF-κB mediated 
upregulation of COX2, TNF, IL1A, MMP9 and chemokines. Also, NF-κB contributes to 
angiogenesis and metastasis by enhancing the expression of ICAM, VCAM, ELAM and VEGF. 
Furthermore, NF-κB activity has been linked to resistance to radiation treatment and 
chemotherapeutic agents through its anti-apoptic activity as well the upregulation of the 
multidrug resistance gene. Thus constitutive NF-κB activity causes perpetuating 
tumorigenesis108,126. 
 
1.8.5 Strategies to target NF-κB activity  
Altered NF-κB activity contributes to carcinogenesis; accordingly, numerous strategies have 
been investigated to target this pathway. Several natural and synthetic compounds have been 
identified to inhibit NF-κB activation pathways as well as DNA binding activity108. Agents 
that block NF-κB DNA binding activity act as transcription factor decoys that bind the 
consensus κB motif and include synthetic peptides, heavy metals as well as natural 
compounds126-128. Other agents that block NF-κB activation do so by promoting the 
upregulation of the inhibitor IκB-α129 as well as inhibit its phosphorylation130 and proteasomal 
degradation131 through steroidal compounds, IKK inhibitors and proteasome inhibitors 
respectively.  
 
Several studies have focused on targeting NF-κB activity in AML using the proteasomal 
inhibitor MG-132 as well as a non-specific IKK inhibitor parthenolide (PTL). Primary AML 
specimens with high NF-κB activity that were treated with these inhibitors displayed a rapid 
induction of cell death while causing no significant toxicity to normal hematopoietic 
cells131,132. The efficiency of targeting NF-κB activity through current available inhibitors in 
AML will be further discussed in chapter 4 with emphasis on new plausible and more 
effective strategies. 
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Table 2. Post-translational modifications of NF-κB transcription factors have diverse 
impacts on functionality.  NF-κB proteins are subject to a multitude of modifications that 
serve as “barcodes” dictating different transcriptional outcomes133.  
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1.9 Hypothesis and Main Objectives 
The inhibition of NF-κB activity with IκB-SR in primary AML and bc-CML specimens 
resulted in a substantial reduction in EIF4E transcript and protein levels70 suggesting that 
EIF4E is downstream to NF-κB. However, the molecular underpinnings of this plausible 
regulation were not investigated. Accordingly, I hypothesized that EIF4E is a direct NF-κB 
transcriptional target and that aberrant NF-κB activity contributes to EIF4E dysregulation in 
AML. To that end, two aims were set.  
 
Aim1: Investigate the mechanism underlying NF-κB mediated regulation of EIF4E using 
hematopoietic cell lines and primary specimens. I also aimed at examining a correlation 
between constitutive NF-κB activity and selective EIF4E dysregulation in AML.  This aim 
will be discussed in chapter 2, which outlines my published manuscript on NF-κB mediated 
EIF4E regulation.  
 
Aim2: Perform a bioinformatics analysis using data from public repositories to identify a 
correlation between elevated EIF4E and NF-κB RELA (p65) mRNA expression in poor 
prognosis AML as well as provide an in depth understanding of EIF4E’s intricate 
transcriptional control mechanisms. This aim will be discussed in chapter 3, which outlines a 
manuscript in preparation on new insights into EIF4E regulation and the association of 
elevated EIF4E and RELA expression with poor patient prognosis in AML.  
 
This thesis delineates novel insights into understanding the transcriptional regulation of EIF4E 
through NF-κB, as well as describes a prognostic association of EIF4E and NF-κB RELA 
expression with clinical outcome in AML. These findings will provide an additional level of 
EIF4E targeting through NF-κB where targeting EIF4E activity with ribavirin is coupled to 
modulating EIF4E expression through NF-κB suppression in AML. 
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Synopsis: The transcriptional control of EIF4E has been viewed, for the past 16 years, as 
Myc-centric; however, EIF4E is still inducible in Myc null fibroblasts. Loss of NF-κB activity 
in M5 acute myeloid leukemia specimens resulted in a downregulation of EIF4E suggesting a 
link between NF-κB activity and EIF4E regulation. In this chapter, I present data supporting 
an NF-κB mediated transcriptional modulation of EIF4E and the molecular mechanisms of 
this control. Furthermore, I present evidence suggesting an NF-κB dependent mechanism 
underlying the differential upregulation of EIF4E in AML.  
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Key Points: 
1) EIF4E is a direct inducible transcriptional target of NF-κB. Its upregulation is 
abrogated with genetic or pharmacological NF-κB inhibition.  
2) NF-κB in M4/M5 AML is strongly and constitutively associated with the EIF4E 
promoter, contributing to its transcriptional upregulation.   
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Abstract 
The eukaryotic translation initiation factor EIF4E is a potent oncogene elevated in many 
cancers including the M4 and M5 subtypes of acute myeloid leukemia (AML). Although 
EIF4E RNA levels are elevated 3-10 fold in M4/M5 AML, the molecular underpinnings of 
this dysregulation were unknown. Here, we demonstrate that EIF4E is a direct transcriptional 
target of nuclear factor kappa-light- chain-enhancer of activated B cells (NF-κB) that is 
dysregulated preferentially in M4 and M5 AML. In primary hematopoietic cells and in cell 
lines, EIF4E levels are induced by NF-κB activating stimuli. Pharmacological or genetic 
inhibition of NF-κB represses activation. The endogenous human EIF4E promoter recruits p65 
and cRel to evolutionarily conserved κB sites in vitro and in vivo following NF-κB activation. 
Transcriptional activation is demonstrated by recruitment of p300 to the κB sites and 
phosphorylated Pol II to the transcriptional start site. In primary AML specimens, generally 
we observe that substantially more NF-κB complexes associate with EIF4E promoter elements 
in M4 and M5 AML specimens examined than in other subtypes or unstimulated normal 
primary hematopoietic cells. Consistently, genetic inhibition of NF-κB abrogates EIF4E RNA 
levels in this same population. These findings provide novel insights into the transcriptional 
control of EIF4E and a novel molecular basis for its dysregulation in at least a subset of 
M4/M5 AML specimens.  
 
Key Words: AML, EIF4E, NF-κB  
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2.1 Introduction 
The eukaryotic translation initiation factor 4E (EIF4E) is a potent oncogene which is 
inappropriately elevated in about 30% of human cancers including the M4 and M5 subtypes of 
Acute Myelogenous Leukemia (AML) and in blast crisis, but not chronic phase, CML1. EIF4E 
overexpression leads to increased proliferation, evasion of apoptosis, oncogenic 
transformation, tumor invasion and metastases 1-5. EIF4E interacts with the methyl-7-
guanosine cap moiety on the 5’ end of mRNAs 6 and via this activity plays a central role in 
cap dependent translation and in nucleo-cytoplasmic export of a subset of transcripts encoding 
proteins involved in cellular growth, survival and transformation such as Cyclin D1, VEGF, c-
myc, Mcl1 and Pim1 7,8. Both the translation and export activities of EIF4E contribute to its 
transformation potential 9. Depletion of EIF4E in cancer cells using siRNA, anti-sense 
oligonucleotides or pharmacological inhibitors leads to cell cycle arrest and decreased 
tumorigenicity 10-13. Targeting of EIF4E with a competitive inhibitor of the m7G cap moiety, 
ribavirin, led to clinical responses in poor prognosis M4 and M5 AML patients, including 
remissions in a phase II trial 10.  
 
Few studies have focused on how EIF4E RNA levels become elevated in malignant cells. In 
M4 and M5 AML specimens, EIF4E RNA and protein levels are elevated by ~ 3-10 fold 
relative to primary hematopoietic cells from healthy volunteers 10. Traditionally, transcription 
of EIF4E was thought to be controlled only by c-Myc 14. Other studies have implicated Sonic 
hedgehog signaling 15 and p53 16 in the control of EIF4E transcription, but these too are 
ultimately considered to be mediated by c-Myc interaction with the EIF4E promoter. 
Interestingly, EIF4E expression is still stimulated in response to serum in Myc null fibroblasts 
indicating that there are other mechanisms to control EIF4E transcription 17. Consistent with 
this idea, a recent report suggests that EIF4E is also a C/EBP target 18. Our previous studies in 
primary M4 and M5 AML specimens suggested a tantalizing link between NF-κB and the 
transcription of EIF4E. Introduction of the NF-κB inhibitor IκB-super repressor (IκB-SR) into 
primary M4 or M5 AML specimens, which are characterized by constitutive NF-κB activity, 
resulted in a substantial reduction in EIF4E transcript and protein levels 19. However to date, 
whether the link between NF-κB and EIF4E was a direct one, had not been investigated. 
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The NF-κB family of transcription factors plays a central role in the regulation of growth, 
proliferation, inflammation and apoptosis 20. Importantly, NF-κB is constitutively active in 
primary AML specimens and this elevation contributes to the leukemogenic phenotype21. NF-
κB members include NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB and cRel and they may 
form homo- or hetero-dimers. In resting cells, NF-κB subunits reside in the cytoplasm, kept 
inactive by the IκB family of inhibitors. Receptor stimulation leads to a signaling cascade that 
culminates in the activation of the IKK kinase complex, which phosphorylates the IκB 
molecules leading to their proteasomal degradation. Free NF-κB dimers translocate into the 
nucleus, where they bind cognate DNA sequences known as κB sites (consensus 5’- 
GGGRNYYYCC-3’) via their Rel homology domain (RHD) to regulate gene transcription 
22,23. Importantly, introduction of a dominant negative repressor of NF-κB, IκB-SR, which 
blocks its nuclear translocation leads to reduced growth of primary AML cells 19.    
 
In this study, we establish that EIF4E is a direct transcriptional target of NF-κB in 
hematopoietic cell lines and primary normal hematopoietic cells. Further, studies in primary 
M4/M5 AML specimens indicate that at least for the specimens examined the EIF4E promoter 
elements are preferentially occupied relative to M1 and M2 AML subtypes with normal EIF4E 
levels or to healthy, unstimulated, hematopoietic cells. These studies suggest that NF-κB 
activation can differentially target subsets of genes in specific AML contexts. These findings 
provide a novel control mechanism for EIF4E expression and a novel basis for its 
dysregulation in AML, and likely in other malignancies characterized by activated NF-κB. 
 
2.2 Materials and Methods 
2.2.1 Primary cell isolation and treatments 
Primary B cells were purchased from Stem Cell Research. Primary AML samples from 
anonymous patients (M1, M2, M4 and M5) were obtained from the BCLQ (Banque de 
Cellules Leucémiques du Québec) with ethics committee approval from the University of 
Montreal (Comité d’éthique de la recherche en santé CEFRM#195). Leukaphereses from 
healthy donors were obtained at the Royal Victoria Hospital, Montreal, Quebec, Canada with 
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ethics committee approval from the Jewish General Hospital and McGill University Research 
Ethics Committee (REC) board of the SMBD-Jewish General Hospital (protocol number# 06-
103). Written informed consent was obtained from both healthy donors and AML patients in 
accordance with the Declaration of Helsinki. Characteristics of the AML primary specimens 
used in this study are presented in Supplementary Table 1. AML cells were thawed in RPMI 
1640 (Invitrogen, Life Technologies, Burlington, ON, Canada) supplemented with 10% heat 
inactivated FBS and 100 U of penicillin/streptomycin (Invitrogen). Nuclear lysates were 
prepared from 4 million cells respectively. 
 
Peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Paque PLUS 
(Invitrogen) according to the manufacturer’s instructions. Cells were re-suspended in RPMI 
1640 (Invitrogen) supplemented with 15% heat inactivated FBS and 100 U of 
penicillin/streptomycin (Invitrogen). Cells were plated at a density of 30 x 106 cells in T75 
flasks and treated with PMA (Phorbol 12-myristate 13-acetate, Sigma, Oakville, ON, Canada) 
at 20 ng/ml for the described time points. For NF-κB inhibition, cells were pretreated for 1 
hour with 10 µM Bay 11-7082 (Sigma) prior to PMA stimulation and the inhibitor was kept in 
the media throughout the experiment. 
 
2.2.2 Cell culture 
BJAB (Burkitt’s cell lymphoma), KG1a (M0 AML) and THP1 (M5 AML) cells were obtained 
from and cultured according to the American Type Culture Collection (ATCC). KM-H2 
(Hodgkin’s) lymphoma cell line was a kind gift from Dr Sigrun Smola. The BJAB cell line 
used was always cultured at low density, maintained at ~70% confluency and kept from 
reaching full confluency. BJAB cells (106 cells in six-well plates) were treated with 20 ng/ml 
PMA (Sigma). NF-kB inhibition was carried out using the Bay 11-7082 (Sigma) by 
pretreating the cells with 10 µM for 1 h before stimulation with PMA. 
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2.2.3 Antibodies and Primers 
The following antibodies were used: p50 (Rockland Immunochemicals, 100-4164; Cedarlane 
Laboratories, Burlington, ON, Canada), RelA (p65) (Rockland Immunochemicals, 100-4165), 
cRel (Cell Signaling no. 4727S, New England Biolabs, Whitby, ON, Canada), p300 (Rockland 
Immuno- chemicals, 100-301-76), EIF4E (BD Transduction laboratory, 610270, Mississauga, 
ON, Canada), S2/5 phospho-RNA polymerase II (Cell Signaling no. 4735S) and β-actin 
(Sigma, A5441). Specific primers designed for gel shift assays, chromatin 
immunoprecipitation (ChIP) and expression analysis are summarized in Supplementary Table 
2. 
 
2.2.4 Promoter Analysis and validation of NF-κB sites 
The human EIF4E promoter sequence was obtained from the Transcriptional Regulatory 
Element Database (TRED, Cold Spring Harbor, http:// rulai.cshl.edu/cgi-
bin/TRED/tred.cgi?process=home). Promoter analysis for transcription factor binding sites 
was performed using MatInspector24 (http://www.genomatix.de/cgi-bin/matinspector_prof/). 
Validation of the putative NF-κB elements was carried out with ChIP and electrophoretic 
mobility shift assays (EMSA). These protocols are described in detail in the supporting text. 
 
2.2.5 Expression Analysis 
Total RNA was isolated from control and treated cells using Trizol (Invitrogen) according to 
the manufacturer’s instructions. RNA was additionally treated with RNase-free DNase I 
(Ambion, Life Technologies). Complementary DNA was synthesized using M-MLV Reverse 
Transcriptase (Invitrogen) and expression analysis was then performed with quantitative real-
time PCR using the StepONE real-time PCR (Applied Biosystems, Life Technologies). Ct 
values were analyzed using the DDCT method25 and normalized to β-Actin, Histone 2B and 
Ubiquitin. Total protein was extracted with RIPA buffer (Tris 50 mM, NaCl 150 mM, SDS 
0.1%, sodium deoxycholate 0.5% and NP-40 1%) and analyzed by western blot using 
chemiluminescence (Thermoscientific, Fisher, Ottawa, ON, Canada). Western blot band 
densities were analyzed with ImageJ software (ImageJ, US National Institutes of Health, 
Bethesda, MD, USA).  
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2.3 Results 
2.3.1 NF-κB activation stimulates EIF4E expression in hematopoietic cell lines 
Our previous studies indicated that EIF4E is highly elevated (~3- to 10-fold) in M4/M5 AML 
specimens but generally not in other AML subtypes or in a variety of primary hematopoietic 
cells isolated from healthy volunteers, including CD34+ cells, granulocytes and 
monocytes10,19,26. Given our previous finding that IκB-SR expression in a primary M5 AML 
specimen repressed EIF4E RNA levels, we investigated the potential role of NF-κB activity in 
the direct transcriptional control of EIF4E. In M4/M5 AML cells, NF-κB activity is 
constitutive thus, we used a hematopoietic cell line BJAB as a model system because of its 
low-basal NF-kB activity, which enabled us to examine the effects of NF-kB activation 22,23,27. 
Cells treated with PMA, an NF-κB stimulator, exhibited a rapid increase in EIF4E mRNA, 
with levels doubling at 3 h (Figure 1A), as determined by quantitative real-time PCR and a 
parallel increase in EIF4E protein levels up to sevenfold was also observed (Figure 1D). 
Known NF-κB targets, MYC and CCND1, also displayed a similar increase (two- to threefold) 
upon PMA stimulation of these cells (Figures 1B and 1C). Given that PMA is a pleiotropic 
agent, we assessed the effects of the pharmacological IKK complex inhibitor Bay 11-7082,28 
which blocks IκBα phosphorylation. The observed induction of EIF4E mRNA expression was 
completely abrogated when samples were treated with Bay 11-7082, consistent with the 
hypothesis that the increase in EIF4E mRNA observed is due to NF-κB activation (Figure 
1A).  
 
2.3.2 The NF-κB subunits cRel and p65 directly alter EIF4E promoter activity. 
We analyzed the human EIF4E promoter (up to 863 bp upstream of the transcriptional start 
site) using bioinformatics (MatInspector24) for the presence of κB sites. Previous analysis of 
the rat EIF4E promoter had suggested the presence of two putative Rel elements but these 
were never examined for activity29. We identified four κB sites (denoted κB1 through 4 in the 
text) centered on positions -836, -808, -630 and -348 relative to the transcriptional start site 
(Figure 2A and Supplementary Figure 2A).   
 50 
 
 
Figure 1. Stimulation of BJAB cells with PMA leads to NF-κB dependent EIF4E 
transcriptional upregulation. BJAB cells at approximately 50% confluency were stimulated 
with PMA (20 ng/mL) for the indicated time points, in the presence (black) or absence (grey) 
of BAY11‐7082 (10 µM). A, B, C) Expression of EIF4E (EIF4E), cMyc (MYC) and cyclinD1 
(CCND1) mRNA was analyzed by Q‐PCR. Results shown are the average of 3 independent 
experiments each performed in triplicate (error bars are s.e.m, p values were calculated using 
the student t-test). D) Immunoblot of EIF4E and cMyc expression following PMA stimulation 
of BJAB cells for the indicated times; β‐actin is provided as loading control. Band intensity 
was quantified with ImageJ.  
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These sites are evolutionary conserved in human, cow, monkey, mouse and rat 
(Supplementary Figure 2B). Note that the NF-κB pathway is absent in yeast and worms 20 
although both express EIF4E suggesting an evolutionary emergence of an NF-κB mediated 
mechanism to induce EIF4E expression in higher organisms. Our analysis also revealed the 
presence of binding sites for several other transcription factors (PU.1, PAX5, Octamer, NF-
AT) (not shown). Although the significance of these novel binding sites needs further 
investigation, they are suggestive of a more intricate transcriptional control of EIF4E than the 
prevailing model of transcriptional regulation solely through Myc.  
 
In order to determine whether activating signals induce binding of NF-κB complexes to the 
putative κB elements in the EIF4E promoter, we carried out electrophoretic mobility shift 
assays (EMSA) using nuclear extracts from BJAB cells in the presence and absence of PMA. 
These cells exhibited low basal levels of NF-κB activity, which could be dramatically induced 
by PMA treatment as determined by EMSA using the kappa light chain consensus motif 
(Figure 2B). At 90 minutes post-stimulation, all four of the predicted κB elements yielded 
inducible complexes when incubated with nuclear extracts (Figure 2C and Supplementary 
Figure 3). The complexes were specific, as they could be competed by excess cold probe 
corresponding to the consensus kappa light chain κB motif 30 (Figure 2C, lane 6), but not with 
a cold probe corresponding to mutant sites for κB3 and κB4 (Figure 2D). Supershift analysis 
with antibodies against p50, p65 and c-Rel revealed cRel/p65 heterodimers bound the 
promoter elements (Figure 2C, lanes 2 and 4). Although some p50 protein was supershifted 
(Figure 2C, lane 3), specific bands corresponding to p50-containing complexes could not be 
detected, suggesting that p50 is not a central component of the bound complexes. These 
experiments demonstrated that all four κB sites in the EIF4E promoter recruit cRel/p65 
complexes.  
 
2.3.3 NF-κB recruits p300 and Pol II to the EIF4E promoter in vivo  
To establish that the NF-κB complexes detected by EMSA formed not only in vitro on EIF4E 
promoter fragments but also in cells, we carried out chromatin immunoprecipitation (ChIP) 
experiments in BJAB cells treated with PMA for one or two hours (Figure 3).   
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Figure 2. The EIF4E promoter contains four κB sites preferentially bound by cRel-p65 
NF-κB complexes. A) Schematic representation of the EIF4E promoter. Predicted κB sites 
(open circles) are indicated. B) Kinetics of NF-κB binding to the consensus κB following 
PMA stimulation of BJAB cells. C) EMSA of nuclear extracts (NE) from PMA-stimulated 
BJAB (90 min) using probes corresponding to κB3 and κB4 sites in the EIF4E promoter. 
Supershift analysis using antibodies against p65, p50, cRel and IgG control as well as 
competition with consensus cold probe (CCP) are indicated. Protein/DNA complexes are 
indicated by arrows, supershifted complexes by arrowheads. Free probe is also shown. D) 
EMSA of nuclear extracts from PMA-stimulated BJAB (90 min) using probes corresponding 
to κB3 and κB4 sites in the EIF4E promoter with cold probe competition using consensus 
cold probe (CCP) or mutant cold probe (MCP).  
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Our results revealed maximum cRel binding at 1 hour post-treatment, with 3-fold enrichment 
at the κB3 site and a 2-fold enrichment at the κB4 site (Figure 3B). The p65 subunit was 
recruited to both sites following 1 hour of treatment with maximal 9-fold and 10-fold 
enrichment at the κB3 and κB4 sites, respectively (Figure 3A). Activated NF-κB (cRel and 
p65) dimers bound to the EIF4E promoter effectively recruited p300 histone acetyl 
transferase, a marker of transcriptionally active NF-κB complexes 31. Maximum p300 
enrichment was again observed one hour post-treatment: 9-fold for κB3 and 7-fold for κB4 
(Figure 3C). In contrast, no binding of NF-κB subunits was detected at the κB1 and κB2 sites 
by realtime PCR at 1 or 2 hours post-PMA treatment (data not shown). This suggests that the 
κB1 and κB2 sites are not active in vivo in this context, possibly due to the chromatin status at 
the EIF4E locus. Phosphorylated Pol II was significantly enriched at the EIF4E coding region 
with 2-fold at 1h and 5-fold at 2h (Figure 3D) confirming enhanced EIF4E gene transcription. 
Thus, shortly after NF-κB stimulation, binding of cRel/p65 dimers at the κB3 and κB4 but not 
κB1 and κB2 sites of the EIF4E promoter results in transcriptional upregulation of EIF4E 
expression via recruitment of p300. 
 
2.3.4 NF-κB activation induces EIF4E transcription in primary human cells 
To examine the biological relevance of our findings to the normal control of EIF4E 
transcription, we assessed EIF4E levels as a function of PMA stimulation in primary PBMCs 
isolated from two healthy individuals (Figure 4, Supplementary Figure 1). PMA induced 
EIF4E mRNA expression as early as two hours with maximal induction at 4 hours (4-fold 
upregulation relative to the untreated controls, Figure 4A). Increased EIF4E mRNA levels 
were observed up to 12 h post-treatment (3-fold). Established NF-κB targets MYC and 
CCND1 mRNAs, had their RNA levels induced following PMA stimulation (Supplementary 
Figure 1A and 1B). Results were similar for EIF4E transcript from another healthy volunteer 
(Figure 4B). Flow cytometry analysis of the same samples revealed a significant increase in 
the population of cells with elevated EIF4E protein levels (Supplementary Figure 1C and 1D).   
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Figure 3. NF-κB complexes are recruited to the EIF4E promoter and promote 
transactivation. BJAB cells were stimulated with PMA for 0, 1 or 2 hours and subjected to 
chromatin immunoprecipitation using antibodies specific for p65 (A), cRel (B), p300 (C) and 
phosphorylated Pol II (Ser2/Ser5) (D). Data were normalized to IgG control and represented 
as fold enrichment with respect to untreated cells. Error bars represent standard deviations 
from triplicate measurements of a representative experiment.   
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Figure 4. PMA Stimulation of primary human PBMCs increases EIF4E expression in an 
NF-κB dependent manner. (A) PBMCs (volunteer1) were stimulated with PMA (20 ng/mL) 
for the indicated time points in the presence or absence of the NF-κB inhibitor Bay 11-7082 
(10 µM). Expression of EIF4E (EIF4E) was assessed at the mRNA level by realtime Q-PCR.   
(B) Same as (A) using PBMCs of a second healthy volunteer. Error bars indicate standard 
deviation. (C, D) Primary B lymphocytes were stimulated with PMA (20 ng/mL) for the 
indicated time points in the presence or absence of the NF-κB inhibitor Bay 11-7082 (10 µM). 
Expression of EIF4E and cMyc (MYC) were assessed at the mRNA level by realtime Q-PCR.  
Results shown are from cells obtained from one healthy donor in triplicate.  
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Upon treatment with the NF-κB inhibitor, Bay 11-7082, we observe that both EIF4E mRNA 
and protein expression were no longer induced by PMA consistent with these effects being 
mediated through NF-κB. Furthermore, EIF4E mRNA was monitored as a function of PMA 
stimulation in primary B lymphocytes as a direct primary companion to BJABs. EIF4E 
transcript doubled at two hours and reached a maximum of 4-fold at 6 hours in an NF-κB 
dependent manner (Figure 4C and 4D).  Thus EIF4E is an NF-κB inducible gene in primary 
hematological cells.  
 
2.3.5 EIF4E transcription is elevated in cells with constitutively active NF-κB 
Many cancers including AML are characterized by constitutively active NF-κB21.  Thus, we 
monitored EIF4E in KM-H2 cells which are hematopoietic cells characterized by 
constitutively active NF-κB, owing to a somatic mutation in the IκBα gene 32. In these cells, 
EMSA analysis revealed constitutive binding of NF-κB to the κB3 and κB4 sites of the EIF4E 
promoter (Figure 5A). Supershift analysis demonstrated the presence of cRel/cRel 
homodimers as well as cRel/p65 heterodimers; some p65/p50 complexes were also detected 
with κB4, although their unusually slow migration pattern was suggestive of the presence of 
an additional unidentified factor(s).  To further demonstrate the direct role of NF-κB in this 
system, we transduced KM-H2 cells with a retroviral vector expressing IκB–SR to block NF-
κB activity. Consistently, IκB-SR reduced EIF4E transcript and protein levels as well as those 
for the c-Myc control (Figure 5B and 5C). Thus, EIF4E transcription is elevated in the context 
of constitutively active NF-κB. 
 
2.3.6 Elevated NF-κB activity in M4 and M5 AML specimens underlies, at least in part, 
EIF4E dysregulation 
To determine whether NF-κB transcriptional activity could underlie elevation of EIF4E in 
primary M4 and M5 AML, we examined NF-κB activity in the AML-M5 cell line, THP1 33, 
characterized by elevated EIF4E 26. Consistent with previous findings 34, THP1 cells harbor 
constitutively active NF-κB.   
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Figure 5.  Constitutively active NF-κB regulates EIF4E expression in KM-H2 cells. (A) 
EMSA analysis of KM-H2 nuclear extracts using probes corresponding to the κB3 and κB4 
sites. Supershift analysis using antibodies against p65, p50, cRel and IgG control as well as 
competition with consensus cold probe (CCP) were done. Protein/DNA complexes are 
indicated by arrows and supershifted complexes by arrowheads. Free probe is also shown. (B) 
KM-H2 cells were transduced with IκB-SR or vector control and EIF4E and cMyc (positive 
control) RNA levels were assessed by Q-PCR. Error bars represent standard deviations. (C) 
Same samples as in (B) were analyzed by immunoblot.  
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Figure 6. NF-κB recognition of the EIF4E promoter elements in AML cell lines. (A) 
EMSA of nuclear extracts prepared from unstimulated THP1 cells (M5 AML) that were 
incubated with the κB elements in the EIF4E promoter. Supershift analysis (arrowheads) using 
antibodies against p65 and cRel as well as competition with consensus cold probe (CCP) are 
indicated. Free probe is also shown. (B) NF-κB complexes are recruited to the EIF4E 
promoter in THP1 and KG1a (M0 AML with high EIF4E) cell lines. Chromatin 
immunoprecipitation was carried out with RelA antibody using chromatin from THP1 and 
KG1a cells. Recruitment to the κB elements as well as a non-specific control region in exon 2 
of EIF4E was monitored by Q-PCR. Data is represented as fold enrichment over IgG. Error 
bars represent standard deviations from triplicate measurements.   
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Nuclear lysates prepared from THP1 cells exhibited NF-κB specific binding for the four 
identified promoter elements (Figure 6A). ChIP analysis performed on these cells revealed 
RelA (p65) enrichment on all NF-κB elements in the EIF4E promoter as seen in Figure 6B but 
not to a random region in exon 2 of EIF4E. Note that given the proximity of the κB1 and κB2 
elements, the ChIP experiment cannot differentiate between these 2 sites and thus is referred 
to as κB1/κB2. Thus, NF-κB is constitutively found on the EIF4E promoter.  
 
Further, we examined NF-κB activity in KG1a cells, a variant AML M0 cell line derived from 
the AML M1 cell line KG135. KG1a cells are characterized by highly elevated EIF4E that is 
mainly nuclear (Supplementary Figures 4A and B). Similar to THP1, nuclear lysates from 
KG1a cells demonstrated NF-κB binding for all four identified promoter elements 
(Supplementary Figure 4C) and ChIP analysis indicated RelA enrichment for all the elements 
(Figure 6B). Thus, elevation of EIF4E by NF-κB activity is not necessarily lineage restricted 
and could also explain how EIF4E levels become elevated in a fraction of other AML 
subtypes characterized by elevated EIF4E. 
 
To assess whether our findings could be translated to patient specimens, we extended our 
studies to primary AML specimens. We observed no substantial differences in constitutive 
NF-κB activity across AML subtypes as determined by EMSA experiments using the 
consensus kappa light chain element consistent with previous reports 21 (Figure 7A). To assess 
if the EIF4E promoter was specifically enriched for NF-κB proteins we carried out EMSA 
experiments with all four promoter elements in these AML specimens. We observed 
complexes highly enriched on the κB3 promoter elements in M4 and M5 specimens (in 2/2 
M4 and 2/2 M5) relative to the M1 and M2 specimens (0/1 M1 and 0/2 M2 specimens), which 
were previously characterized by normal EIF4E levels 26 (Figure 7A and Supplementary Table 
1). Consistently, the κB4 element was preferentially occupied in M4 and M5 specimens 
relative to the M1 and M2 specimens (Figure 7A). Further, we observed supershifts using 
antibodies to RelA and c-Rel consistent with these being NF-κB complexes with predominant 
RelA species (Figure 7B). Additionally, M4/M5 nuclear lysates strongly bound the κB1 and 
κB2 elements (Figure 7C).   
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Figure 7. Selective NF-κB recognition of the EIF4E promoter elements in M4/M5 AML. 
EMSA of nuclear extracts prepared from unstimulated PBMCs from a healthy volunteer 
(Norm) and different M1, M2, M4 and M5 AML primary specimen (corresponding to UPN 
samples 1-4 as presented in supplemental table1) incubated with consensus κB motif or with 
the κB3 and κB4 elements (A). (B) Supershift analysis (κB3 /κB4) (arrowheads) using 
antibodies against p65 and cRel as well as competition with consensus cold probe (CCP) are 
indicated. The asterisk (*) indicates a break in the gel during drying. (C) EMSA of nuclear 
extracts prepared from M2, M4 and M5 AML primary specimen incubated with κB1/κB2 
elements. Supershift analysis (arrowheads) using antibodies against p65 and cRel as well as 
competition with consensus cold probe (CCP) are indicated. Free probe is also shown. (D) 
Chromatin immunoprecipitation was carried out with Rel A antibody using chromatin from 
the different specimen (Norm, M2, M4 and M5) used in (A). Recruitment to the κB elements 
was monitored by Q-PCR. Data were normalized to the IgG control and depicted as fold 
enrichment with respect to the normal healthy specimen (Norm). Error bars represent standard 
deviations from triplicate measurements.  
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This is consistent with our previous findings that EIF4E RNA and protein levels are 
preferentially elevated in M4 and M5 relative to M1 and M2 AML subtypes with 
approximately 44/44 M4/M5 AML specimens and 2/22 M1/M2 AML specimens relative to 5 
healthy controls 1,10,19,26.  
 
To assess the functional relevance of these associations we used ChIP analysis performed to 
monitor RelA recruitment in the examined AML samples. RelA was recruited to κB1/κB2 and 
κB3 but not κB4 in the M4/M5 samples but not the M2 (Figure 7D). Although all four 
elements were bound by nuclear lysates from PMA-induced BJABs as well as the NF-κB 
constitutive AML cell line (THP1) and primary specimens through EMSA assays, ChIP assays 
revealed RelA recruitment to the κB1/κB2 elements in only the AML primary specimens and 
cell line but not in BJAB cells implying a lineage specific recognition for NF-κB proteins on 
the EIF4E promoter. Importantly, κB3 elements were also bound in the ChIP assays indicating 
these likely play important roles as well.  
 
Thus, EIF4E promoter elements specifically recruit NF-κB complexes enabling increased 
EIF4E transcription relative to other AML subtypes. Consistently, previous studies showed 
that introduction of IκB-SR into primary M4 and M5 AML specimens resulted in reduced 
EIF4E mRNA and protein levels 19. It seems likely that NF-κB dysregulation in at least a 
subset of M4/M5 AML underlies, at least in part, aberrant elevation of EIF4E RNA levels in 
the evaluated samples. Clearly, more specimens will need to be examined to determine the 
generality of these findings. 
 
2.4 Discussion 
This study reveals novel insights into the control of EIF4E transcription in primary 
hematopoietic cells as well as its dysregulation in AML specimens. These are the first studies 
to show that EIF4E is a transcriptional target of NF-κB. Recently, C/EBP has also been shown 
to regulate EIF4E transcription 18 and thus NF-κB and C/EBP serve as examples that the 
transcriptional control of EIF4E, thought for nearly 16 years to be solely the purview of c-
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Myc, is more complicated.  These findings suggest that there could be eventual clinical utility 
in controlling the transcription of EIF4E with the use of NF-κB inhibitors in addition to 
directly inhibiting EIF4E activity with ribavirin 10,12,26,36,37. Interestingly, many NF-κB target 
genes are in fact EIF4E mRNA export and/or translation targets (e.g. MYC and CCND1) 
suggesting these pathways cooperate to drive proliferative gene expression. Our results have 
shown that genetic and pharmacological inhibition of NF-κB result in downregulation of 
EIF4E targets suggesting that there is a nexus between transcriptional and post-transcriptional 
gene expression networks to modulate cell proliferation.  
 
Beyond the control of EIF4E, our findings strongly suggest that NF-κB activity is likely 
heterogeneous amongst AML specimens with regard to other targeted promoters. In other 
words, the NF-κB dependent transcription of factors besides EIF4E may be differentially 
regulated between AML subtypes, potentially contributing to differences in leukemogenic 
potential. In this way, the kappa light chain occupancy may not be altered amongst subtypes as 
it is dependent on Rel components, but differences in the sequences of other promoters may 
lead to increased dependency of these promoters on non-Rel components for transcriptional 
activation. Furthermore, the selective in vivo recruitment of RelA to the κB1/2 region in the 
M4/M5 AML specimens as well as the M5 AML THP1 cell line but not in the lymphocytic 
BJAB cells could be due to lineage differences. However, this is not strictly lineage restricted 
as ChIP studies indicate that in the high EIF4E AML cell line KG1a, enrichment on the κB1/2 
binding elements is also observed. These differences could underlie the constitutive EIF4E 
upregulation in M4/M5 AML and suggest that non-Rel components play a role in this process. 
Finally, we did not have access to sufficient primary M3 AML (APL) specimens to examine 
NF-κB activity and thus cannot exclude that this is relevant to this leukemia subtype. 
However, primary APL specimens and NB4 cells are characterized by normal EIF4E levels 
and localization suggesting this may not be critical 19,38.  
 
Thus, specific non-Rel transcriptional co-factors of NF-κB may be specifically dysregulated in 
M4 and M5 AML, allowing preferential dysregulation of EIF4E, and potentially other 
promoters. These factors may be involved in the selective NF-κB recruitment to the EIF4E 
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promoter. Examples of non-Rel proteins shown to selectively modulate DNA recognition and 
transactivation of NF-κB proteins in other contexts include: RPS3, CD40, BAFFR, Akirins, 
CHFR, PKAIP, AEG-1, ING-4 and others (Reviewed in 39). Future studies should reveal the 
identity of non-Rel co-factors, which likely preferentially drive transcription of EIF4E in M4 
and M5 AML. In addition to its role in the control of EIF4E expression as outlined here, NF-
κB can also regulate EIF4E activity indirectly by modulating its subcellular localization and 
thus affecting EIF4E levels and activity 19. 
 
2. 5 Conclusion 
In summary, we observe in normal primary hematopoietic cells and in cell lines with normal 
NF-κB activity, that EIF4E transcription is stimulated by NF-κB activation. We demonstrate 
that EIF4E is a direct transcriptional target of NF-κB. We observe that in the M4 and M5 
AML specimens examined, the EIF4E promoter is highly occupied by NF-κB complexes. 
These studies elucidate a novel mechanism of transcriptional control for EIF4E and thus 
potentially a new point at which to target it.  
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Supplementary Material 
Preparation of nuclear extracts  
Cell fractionation was performed with a modification from Dignam et al (Dignam JD et al. 
1983. Nucleic Acid Research). Cells were pelleted and washed twice with PBS. Lysis was 
performed for 10 minutes on ice in hypertonic buffer A (10mM HEPES, pH 7.9, 1.5 mM 
MgCl2, 10mM KCl, 0.5 mM DTT, 0.1 % NP-40 and complete protease inhibitors). The lysate 
was then cleared by centrifugation at 14,000 rpm for 10 minutes at 4° C. The nuclear pellet 
was washed once with buffer A without NP-40 to remove any cytoplasmic contaminants and 
lysed for 10 minutes on ice in high salt buffer B (20mM HEPES, PH 7.9, 420mM NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 10 % glycerol and complete protease inhibitor). 
Nuclear proteins were collected in the supernatant after centrifugation at 14,000 rpm for 10 
minutes at 4° C. The samples were then diluted in ice cold buffer C (20mM HEPES, pH7.9, 
20% glycerol, 0.2mM EDTA, 50 mM KCl, 0.5 mM DTT and complete protease inhibitor), 
aliquoted and stored at -80° C. 
 
EMSA  
Oligonucleotide labeling: Double stranded oligonucleotides corresponding to the consensus 
NF-κB motif and the putative NF-κB elements identified in the EIF4E promoter were 
prepared by annealing of the sense and antisense sequences at 10 pmol/ul final concentration 
in TEN buffer (10mM Tris, pH 7.8, 1mM EDTA and 50mM NaCl) at 95° C for 5 minutes, 
followed by cooling down to room temperature. The labeling reaction was then carried out 
with T4 kinase (Invitrogen) for 90 minutes using 15pmol of double stranded oligonucleotides 
and 25uCi of γ32 ATP. 
 
Preparation and resolving the binding reaction: 5 ug of nuclear extracts were incubated with 
the labeled double stranded probes (at 200,000 cpm) in NF-κB binding buffer (10mM Tris, pH 
7.8, 50mM NaCl, 0.5 mM EDTA, 1mM DTT, 10% glycerol, 2mM ATP and 2mM GTP) for 
20 minutes at room temperature. For supershift experiments, 2ug of antibody (p65, p50 and c-
Rel) was added to the reaction mixture. Cold probe competition was performed with 200x 
excess of unlabeled oligonucleotides. The reactions were resolved on a 5% non-denaturing 
polyacrylamide gel (19:1 crosslink, 0.5x TAE and 5%glycerol) in Tris-actetic-EDTA (TAE) 
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buffer. The gel was run for 3 hours at 150 volts after which it was dried for 2 hours using a 
BioRad gel dryer and then exposed overnight on a Fugifilm imaging plate for detection. 
 
ChIP 
Crosslinking: Cells were crosslinked for 20 minutes at room temperature on a rocking 
platform with 1/10 volume Formaldehyde solution (11% Formaldehyde, 100mM NaCl, 1mM 
EDTA, 0.5mM EGTA and 50mM HEPES pH 7.4). Quenching was performed for 5 minutes 
with 1/20 volume 2.5 M Glycine. The crosslinked samples were then pelleted by 
centrifugation at 1,200 rpm for 5 minutes at 4° C and washed twice with PBS. 
 
Cell lysis and Sonication: The pelleted cells were first lysed in cytoplasmic lysis buffer for 10 
minutes on ice (0.005 mM PIPES, 85 mM KCl, 0.5% NP-40 and complete protease inhibitor). 
Following clarification at 4,000 rpm for 5 minutes at 4° C, the nuclear pellet was washed once 
with cytoplasmic lysis buffer with out NP-40 to remove cytoplasmic contaminants. Nuclear 
chromatin was then harvested by incubating with nuclear lysis buffer for 10 minutes on ice 
(50mM Tris, pH 8, 10mM EDTA, 1% SDS and complete protease inhibitor). Sonication was 
then carried out using a waterbath Bioruptor at 4° C. Four rounds were performed: eight 
minutes each at 30 seconds intervals on medium power. The samples were then cleared by 
centrifugation at 10,000 rpm for 10 minutes at 4° C. This sonication protocol produces sheared 
chromatin between 200 and 500 bp. 
 
Pre-clearing and Chromatin Immunoprecipitation: Protein A/G beads were first pre- blocked 
with 200 ug salmon sperm DNA (Sigma) and 500 ug BSA (Sigma) for 3 hours at 4° C with 
rocking. 50 ug of chromatin was diluted in Immunoprecipitation buffer to a final volume of 
1ml (IP buffer: 10% Triton-X, 1.2 mM EDTA, 16.7mM Tris pH 8, 167 mM NaCl and 
complete protease inhibitor). 10ul of cell lysate was conserved as 1% Input. Chromatin pre-
clearing was performed with pre-blocked Protein A/G agarose beads (Santa Cruz 
biotechnologies) for 1hour at 4° C with rocking. Pre-cleared chromatin was then incubated 
with 10ug of antibody (p65, c-Rel and p300) overnight at 4° C with rocking. The samples 
were then centrifuged at 13,000 rpm for 10 minutes (this step ensures the removal of insoluble 
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chromatin material) and the supernatant was incubated with pre-blocked protein A/G agarose 
beads for 2 hours at 4° C with rocking. 
 
Sample elution and realtime PCR: Following immunoprecipitation, the beads were washed 
twice with wash buffer 1 (2 mM EDTA, 50 mM Tris pH 8, 0.2% Sarkosyl) followed by two 
washes with wash buffer 2 (500 mM LiCl, 1% NP-40, 1% Sodium deoxycholate and 33 mM 
Tris, pH 8). Elution was carried out with 100 ul of 10% chellex slurry (BioRad) at 95° C for 
15 minutes. The samples were then cleared at 13,000 rpm for 1 minute and treated with 20 ug 
of Proteinase K (Sigma) for 1 hour at 55° C with shaking. Final purification with Qiagen PCR 
purification kit was then performed. Input DNA was purified with 10% chellex beads at 95° C 
followed by proteinase K treatment and sample purification. Realtime quantitative PCR was 
then perfomed with Syber Green (Invitrogen) and primers flanking the putative NF-κB 
elements in the EIF4E promoter using the Step one thermal cycler from Applied Biosystems. 
CT values were analyzed with the DDCT method and normalized relative to IgG (Haring M et 
al. 2007. Plant Methods). 
. 
Supplemental Figure 1. (A) Expression of positive controls cMyc (MYC) and cyclinD1 
(CCND1) were assessed at the mRNA level by realtime Q-PCR. (B) Same as (A) but from 
PBMCs from a second volunteer. (C, D) EIF4E protein levels from the PBMC samples 
(Figure 4) were analyzed by flow cytometry to assess cell populations with high EIF4E protein 
levels. 
 
Supplemental Figure 2. The EIF4E promoter harbors 4 NF-κB elements. A) Nucleotide 
sequence and position relative to the transcriptional start site (+1) of the four κB sites 
predicted in the EIF4E promoter. B) Sequence alignment showing species conservation of κB 
elements. 
 
Supplemental Figure 3. Electromobility shift assay of BJAB nuclear extracts stimulated 
with PMA (20 ng/mL). EMSA of BJAB cells stimulated with PMA for 90 minutes using κB1 
and κB2 probes. Supershift analysis was done with the indicated antibodies. 
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Supplemental Figure 4. EIF4E is elevated with nuclear localization in the M0 AML cell 
line KG1a. A) Western blot from whole cell lysates obtained from: a normal volunteer as well 
as THP1 (M5), KG1a (M0) and an M1 AML specimen. The panels are obtained from the same 
western blot but with intervening unrelated samples cropped out. Thus there is a space 
between the two parts of the gel. B) Confocal imaging performed on KG1a and THP1 cells as 
well as a normal and an M5 AML specimen. C) EMSA of nuclear extracts prepared from 
unstimulated THP1 and KG1a that were incubated with the κB elements in the EIF4E 
promoter. Free probe is shown. PC is phase contrast. 
 
Supplementary Table 1. List of the AML patient specimens and cell lines used in this 
study. ITD, internal tandem duplications. UPN, unidentified patient number. Not available 
NA. THP1 (ATCC-TIB202). KG1a (ATCC-CCL246.1) referenced in [Koeffler HP, Billing R, 
Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute 
myelogenous leukemia cell line (KG-1). Blood. 1980 Aug;56(2):265-73.] 
(*) Referenced in [Odero MD, Zeleznik-Le NJ, Chinwalla V, Rowley JD. Cytogenetic and 
molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 
translocation. Genes Chromosomes Cancer. 2000 Dec;29(4):333-8.] 
 
Supplementary Table 2. List of oligonucleotide sequences used in this study.
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Prom&kB3!
Prom&kB4!
Supplemental Figure 2.  !
κB Element                 Sequence                                 Position!
Prom-κB1                 GTGGCTTCCC                              -836!
!
Prom-κB2                 GGCTATTTCC                               -808!
!
Prom-κB3                 GGGCGGTTCC                             -630!
!
Prom-κB4                 AGGCTTGCCT                              -348!
A.!
B.!
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Supplemental Table1.  
Supplemental Table 1. AML patient specimens used in this study. (ITD, internal tandem 
duplications, unidentified patient number UPN, not available NA). * Odero MD, Zeleznik-Le NJ, 
Chinwalla V, Rowley JD. Cytogenetic and molecular analysis of the acute monocytic leukemia cell 
line THP-1 with an MLL-AF9 translocation. Genes Chromosomes Cancer. 2000 Dec;29(4):333-8.!
Pa8ent!!!!!!!!!Subtype!!!!!!!Age!!!!!!eIF4E!(RNA/Protein)!!!!!!Cytogene8cs!!!!!!!Flt3!!!!!!!!NPM!!!!!!!!!!Other!!!!!
UPN1!!!!!!!!!!!!!!!!!!!!!M4!!!!!!!!!!!!!!!!!!61!!!!!!!!!!!!!!!!!!!High!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,XX!!!!!!!!!!!!!!!!!!!!ITD!!!!!!!!!!Mutated!!!!!!!!!!!!&!!!!!!!!!!!!!!!!!!!!!!!!
!
UPN2!!!!!!!!!!!!!!!!!!!!!M5!!!!!!!!!!!!!!!!!!50!!!!!!!!!!!!!!!!!!!High!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,XY!!!!!!!!!!!!!!!!!!!!None!!!!!!!Mutated!!!!!!!!!!!&!
!
UPN3!!!!!!!!!!!!!!!!!!!!!M1!!!!!!!!!!!!!!!!!!45!!!!!!!!!!!!!!!!!!!Normal!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,XX!!!!!!!!!!!!!!!!!!!!None!!!!!!!Mutated!!!!!!!!!!!&!
!
UPN4!!!!!!!!!!!!!!!!!!!!!M2!!!!!!!!!!!!!!!!!!47!!!!!!!!!!!!!!!!!!!Normal!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,!XX!!!!!!!!!!!!!!!!!!!!ITD!!!!!!!!!!Mutated!!!!!!!!!!!&!
!
UPN5!!!!!!!!!!!!!!!!!!!!!M4!!!!!!!!!!!!!!!!!!38!!!!!!!!!!!!!!!!!!!High!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,!XX!!!!!!!!!!!!!!!!!!!!NA!!!!!!!!!!!NA!!!!!!!!!!!!!!!!!!!!!&!
!
UPN6!!!!!!!!!!!!!!!!!!!!!M5!!!!!!!!!!!!!!!!!!48!!!!!!!!!!!!!!!!!!!High!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,!XY!!!!!!!!!!!!!!!!!!!!!ITD!!!!!!!!!!Mutated!!!!!!!!!!&!
!
UPN7!!!!!!!!!!!!!!!!!!!!!M2!!!!!!!!!!!!!!!!!!73!!!!!!!!!!!!!!!!!!!Normal!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,!XY!!!!!!!!!!!!!!!!!!!!!ITD!!!!!!!!!!Mutated!!!!!!!!!!&!
!
THP1!!!!!!!!!!!!!!!!!!!!!!M5!!!!!!!!!!!!!!!!!!!1!!!!!!!!!!!!!!!!!!!!!High!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,!XY!!!!!!!!!!!!!!!!!!!!!NA!!!!!!!!!!!NA!!!!!!!!!!!!!!!MLL&AF9*!
!
KG1a!!!!!!!!!!!!!!!!!!!!!!M0!!!!!!!!!!!!!!!!!!59!!!!!!!!!!!!!!!!!!!!High!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!46,!XY!!!!!!!!!!!!!!!!!!!!NA!!!!!!!!!!!NA!!!!!!!!!!!!!!!!!!!!&!
!!!!!!!
!
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EMSA%
Consensus!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AGTTGAGGGGACTTTCCCAGG!!
Consensus!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CCTGGGAAAGTCCCCTCAACT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!NA!
!
Prom&kB1!!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CCGGAGTGGCTTCCCTGGCT!
Prom&kB1!!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AGCCAGGGAAGCCACTCCGG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!NA!
!
Prom&kB2!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ACTTAGGCTATTTCCGTGCA!
Prom&kB2!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TGCACGGAAATAGCCTAAGT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!NA!
!
Prom&kB3!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GTACTGCGGGCGGTTCCGTCC!
Prom&kB3!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GGACGGAACCGCCCGCAGTAC!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!NA!
!
Prom&kB4!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ACAGTAGGCTTGCCTGGCAGT!
Prom&kB4!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ACTGCCAGGCAAGCCTACTGT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!NA!
!
!
ChIP%
Coding!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TTCAACTCCCGACCTCAGGT!
Coding!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ATAACTAGCCTGTGCACAAG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!56!°C!
!
Prom&kB1/2!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AGTGGCTTCCCTGGCTGGCAT!
Prom&kB1/2!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GAGATTAAGACCTCAGGGCTA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!56°C!
!
Prom&kB3!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TCAGGATTTGGGACAGTAAAAGCTG!!
Prom&kB3!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CATTTCTGCGAAAGGGGACG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!56°C!
!
Prom&kB4&!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TGCTGAGCCTGCAGTTCCCA!
Prom&kB4!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CTCTGCTCTTCCGCCTGGAT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!56°C!
!
eIF4E&exon2&Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GAAACCACCCCTACTCCTAA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!56°C!
eIF4E&exon2&Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TACCTGTTCTGTAGGGGATG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!56°C!
!
!
mRNA%expression%
Ac8n!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GCATGGAGTCCTGTGGCAACCACG!
Ac8n!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GGTGTAACGCAACTAAGTCATAG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!60!°C!
!
eIF4E!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CTGTGCCTTATTGGAGAAT!!
eIF4E!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GGAGGAAGTCCTAACCTTT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!60!°C!
!
Myc!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TCAAGAGGCGAACACACAACG!
Myc!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TGGACGGACAGGATGTATGCTG!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!60!°C!
!
Pim1!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ACAGGTTGGGATGGGATAGGAC!
Pim!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GAGAAGCAGCAGGTAAAAGAGGC!!!!!!!!!!!!!!!!!!!!!!!!!!!!60!°C!
!
H2B!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!GATGCCTGAACCTACCAAGTC!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!60!°C!
H2B!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ACTGAATAGCTCTCCTTGCG!60!°C!
!
CyclinD1!Fw!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CAGCGAGCAGCAGAGTCCGC!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!60°C!
CyclinD1!Rev!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!ACAGGAGCTGGTGTTCCATGGC!
!
Primer!!!!!!!!!!!!!!!!!!!!!!!!!!!Sequence!!!!!!!!!!!!!!!!!!!!!!!!!!!!!T!annealing!
Supplemental Table 2. Primer sequences.!
Chapter 3: Analysis of public gene expression and transcription factor binding 
data reveals a correlation between NF-κB and EIF4E mRNA expression levels in 
AML and unravels an intricate control mechanism for EIF4E 
 
 
Synopsis: This chapter outlines a bioinformatics analysis of data available from public 
repositories. It constitutes a follow-up on my previous findings that demonstrate an NF-κB	  mediated	   regulation	   of	  EIF4E. Here, I describe an association between NF-κB RELA and 
EIF4E mRNA expression in poor prognosis AML patients as well as its impact on survival 
outcomes. Furthermore, I present an analysis of ChIP-Seq datasets to predict putative EIF4E 
regulators as well as predict new putative NF-κB target genes that may be regulated in an 
EIF4E-like manner. This chapter is presented as a manuscript in preparation. 
 
Contributions:   
All of the original data used in this manuscript have been cited appropriately. 
The analysis presented in all of the Figures was performed by Fadi Hariri (100%). 
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Abstract 
EIF4E is a powerful oncogene that is overexpressed in 30% of human cancers including 
hematopoietic malignancies. Our previous findings suggest that EIF4E is a direct NF-κB 
transcriptional target that is dysregulated in acute myeloid leukemia (AML). EIF4E and NF-
κB RELA mRNA levels are upregulated in AML; however, the correlation between the 
expression patterns of these oncogenes has not been studied in AML risk groups. Analysis of 
gene expression RNA-Seq data from The Cancer Genome Atlas (TCGA) suggests that EIF4E 
and RELA mRNA levels are upregulated in intermediate and poor prognosis AML but not in 
the cytogenetically favorable group. Additionally, elevated EIF4E and RELA mRNA levels 
are significantly associated with worst patient survival outcome.  Using the κB sites in the 
EIF4E promoter, 8 new putative NF-κB target genes were in silico predicted from RelA ChIP-
Seq datasets available from the Encyclopedia of DNA Elements (ENCODE). These genes are 
upregulated in poor prognosis AML similar to EIF4E. Finally, 6 new transcription factors that 
may be implicated in EIF4E gene regulation were predicted from the analysis of ChIP-Seq 
ENCODE data. Collectively, these findings provide insights into the transcriptional control of 
EIF4E and the molecular basis for its dysregulation in poor prognosis AML specimens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Acute myeloid leukemia (AML), microarrays, RNA-Seq, ChIP-Seq, EIF4E, 
NF-κB RelA. 
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3.1 Introduction 
The oncogenic translation initiation factor EIF4E can be thought of as a pivotal molecular 
bridge that facilitates the functional expression of growth-promoting genes (e.g. MYC, 
CCND1, PIM1 and many more). The molecular basis of EIF4E functions at the mRNA export 
and protein synthesis levels has been extensively studied accelerating the route to EIF4E 
clinical targeting in cancer1,2. However, the body of data describing the regulation of EIF4E 
expression in normal cells and how it becomes dysregulated in cancer has not been extensive. 
Furthermore, it offered a c-Myc centric-transcriptional control model3. We have identified an 
alternative mechanism for EIF4E transcriptional regulation that was supported by data 
suggesting an NF-κB mediated regulation4.  
 
EIF4E is overexpressed in approximately 30% of human cancers including hematological 
malignancies and solid tumors. This aberrant upregulation of EIF4E expression has been 
shown to involve EIF4E transcript and protein5,6. In addition, NF-κB is constitutively activated 
in a plethora of cancers, which has been linked to increased expression of NF-κB transcription 
factors7. In acute myeloid leukemia (AML), the NF-κB factor RelA (p65) is upregulated 
owing to a gene amplification as a result of a trisomy in chromosome 11. This has been linked 
to poor prognosis in AML as the overall 10-year survival outcome for AML patients with this 
anomaly was 10%; the overall survival outcome for AML patients in the same study group 
with a non-complex karyotype was 37%8. Interestingly, aberrant EIF4E and RELA expression 
levels overlap in cancer including acute myeloid leukemia. 
 
Acute myeloid leukemia is a hematological malignancy affecting the myeloid lineage of blood 
cells; this malignancy affects the immature myeloid population of cells (myeloblasts) that 
expand at the expense of normal cells9. For the past four decades, AML has been classified on 
the basis of the type of cell from which the leukemia has developed into 9 distinct groups (M0 
through M7); this classification is referred to as the French-American-British classification 
(FAB)10. However, this system has been subject to criticism, revisions and re-assessment since 
the techniques required in classifying AML samples into FAB groups are very descriptive and 
rely on cell morphological features as well as simple cytochemical assays11. On the other 
hand, AML can further classified into three clinical prognosis groups (favorable, intermediate 
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and poor prognosis) based on cytogenetic analysis8. This cytogenetic classification was further 
diversified by molecular mutations into five prognosis groups (very favorable, favorable, 
intermediate, unfavorable and very unfavorable)12 [reviewed in Chapter 1.6.1].  Accordingly, 
the combined cytogenetic and molecular classification offer a more reliable and clinically 
relevant approach to determine prognostic parameters and plan more effective treatment 
regimen8,13. The predicted overall survival outcome in AML patients from a TCGA-AML 
study14 is shown in Supplementary Figure 1A.  
 
Our findings in AML revealed that EIF4E is overexpressed in most M4/M5 AML primary 
specimens but not in most M1/M2 specimens15-17. This trend may be underlined by a selective 
NF-κB activity on the EIF4E promoter in those subtypes4. Both EIF4E and RELA expression 
are upregulated in AML8,18,19; however, the correlation between the expression patterns of 
these oncogenes has not been investigated in clinical prognosis AML groups.  
 
The NF-κB mediated regulation of EIF4E is the product of direct transcriptional control 
inherent in the recruitment of NF-κB transcription factors: RelA (p65), cRel and NFκB1 (p50) 
to four conserved κB elements in the EIF4E promoter. Interestingly, a lineage specific 
requirement for κB elements in the EIF4E promoter exists with a myeloid requirement for all 
binding elements and a preference for κB3 and κB4 sites in mature B-lymphocytes4. 
Additionally, two intronic κB elements were identified and validated by gel shift (EMSA) 
experiments to engage NF-κB proteins. This unpublished observation may imply a more 
elaborate control of EIF4E in response to different NF-κB inducing stimuli as NF-κB 
dependent regulation of target genes has been shown to occur through promoter binding sites 
as well as intronic regions20-22. Finally, the EIF4E promoter is enriched for a plethora of 
transcription factor binding sites23 (e.g. PU.1, NFAT, GATA, SP1) further re-enforcing that 
EIF4E transcriptional control is not “factor” centric and likely involves an interplay of 
transcriptional regulators.  
 
With the advancement of high throughput technology, many databases provide large datasets 
for gene expression and transcription factor binding studies.  Accordingly, We hypothesized 
that the analysis of these public repositories will identify a correlation between elevated 
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EIF4E and RELA mRNA expression in poor prognosis AML as well as provide an in 
depth understanding of EIF4E’s intricate transcriptional control mechanisms. To that 
end, two aims were set: 
 
Aim1: Analyze microarray and RNA-Seq gene expression profiles from AML to determine a 
correlation between EIF4E and RELA gene expression in different clinical prognosis groups. 
Furthermore, the survival outcomes for AML patients with high versus low EIF4E/ RELA 
expression levels will be determined.  
 
Aim2: Analyze NF-κB ChIP-Seq data to establish an NF-κB binding profile across the EIF4E 
locus in the promoter and introns. In addition, this study aims at performing a genome wide 
motif scanning using the identified NF-κB binding sites in the EIF4E promoter and intron to 
predict new candidate genes that may be regulated through NF-κB in a manner similar to 
EIF4E. Given the transcription factor wide nature of the Encyclopedia of DNA Elements 
(ENCODE) ChIP-Seq experiments, we will predict, if possible, the recruitment of other 
transcription factors to the EIF4E regulatory locus.  
 
3.1.1 Public Databases and Limitations 
Microarrays and RNA-Seq have been implemented for the diagnosis and prognosis of AML. 
This area of research has been critical in reshaping our understanding of the development and 
pathogenesis of AML as well as predicting therapeutic response and identifying the underlying 
mechanism of action24,25. Furthermore, the advent of DNA sequencing technologies 
(NextGEN sequencing) and transcription factor association experiments gave rise to 
Chromatin Immunoprecipitation (ChIP) followed by high-throughput sequencing (ChIP-Seq), 
enabling the large-scale identification of transcription factor localization and histone 
modification across the genome26. 
 
The available gene expression databases include MedSapiens27, the Gene Expression Omnibus 
(GEO) and The Cancer Genome Atlas (TCGA)14 and ENCODE28. Despite the wealth of 
information available from these databases, several limitations must be considered as they can 
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largely interfere with the analysis of these data as well as impact the drawn conclusions. For 
instance, the available gene expression data reflects the mRNA pool and not protein levels. 
Similarly, data regarding protein activity (NF-κB for instance) is also lacking. The technical 
limitations must also be considered. For instance, the microarray technology is limited by high 
background owing to cross hybridization, probe specificity, and a limited dynamic range of 
detection (compressed expression levels) due to signal saturation; however, these limitations 
are overcome in RNA-Seq experiments. On the other hand, RNA-Seq data is also affected by 
the sequencing depth and bioinformatics analysis and sequence mapping29. The available 
ChIP-Seq data is limited to particular cell lines and transcription factors as well as antibody 
specificity; additionally, technical analytical limitations exist in the process of transcription 
factor peak calling30,31. Finally, not all public datasets provide detailed sample information; in 
addition, the raw data for the deposited experiments is not always available. These limitations 
must be taken into consideration and controlled for when applicable to derive critical 
conclusions.  
 
In this study, a comprehensive analysis of microarray datasets in AML determined a positive 
correlation between EIF4E and NF-κB RELA mRNA levels. Furthermore, the median EIF4E 
and RELA expression is upregulated in intermediate and poor prognosis AML compared to 
favorable prognosis samples and predicts worst overall survival outcomes in those samples. 
NF-κB ChIP-Seq analysis revealed a complex pattern of NF-κB RelA recruitment to the 
EIF4E promoter.  Using the κB sites in the EIF4E regulatory regions, 46 new putative NF-kB 
target genes were in silico predicted from RelA ChIP-Seq datasets available from ENCODE. 
Finally, 6 new transcription factors that may be implicated in EIF4E gene regulation were 
predicted from the analysis of ChIP-Seq ENCODE data. Collectively, these findings provide 
novel highlight the complexity of EIF4E transcriptional control as well as implicate elevated 
EIF4E and RELA mRNA levels in poor patient prognosis in AML.  
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3.2 Methods for acquisition and processing of public gene expression and transcription 
factor binding data 
3.2.1 Choice and mining of datasets 
The gene expression data discussed in this chapter was obtained from two online public 
repositories. The public microarray raw data used in my analysis was downloaded from the 
National Center for Biotechnology Information (NCBI) GEO website 
(http://www.ncbi.nlm.nih.gov/geo) as well as the TCGA. Two datasets were considered: 
GSE1035832 (microarray) and TCGA_LAML_exp_GA14 (RNA-Seq). ChIP-Seq datasets were 
obtained from the ENCODE repository (http://genome.ucsc.edu/ENCODE/).  
 
3.2.2 Microarray data analysis in R Bioconductor 
The raw microarray dataset was analyzed using Bioconductor packages33 in the R 
programming language.  All datasets used were generated with Affymetrix gene chips 
(U133A). Initially, an assessment for the quality was performed using the SimpleAffy package 
(http://bioinformatics.picr.man.ac.uk/simpleaffy) to ensure a comprehensive and unbiased 
interpretation of the microarray data. Several factors can affect the quality of the data 
generated by each array and these include: mRNA degradation, errors in sample loading 
across different arrays in an experiment and bias arising during array scanning. Accordingly, 
any sample or array that did not match proper quality standards was discarded as no valid 
interpretation can be obtained from a degraded or compromised sample34.  
 
Next, data preprocessing and normalization was performed using the Affy package35 with the 
popular Robust Multi-Array Analysis (RMA) method to account for systematic differences 
across arrays. This method uses a linear model to correct the background, normalizes and logs 
(base 2) the Perfect Match (PM) probe intensities34. Finally, each array is then annotated with 
the human gene names corresponding to each probe using the Annotate package. Statistical 
analysis was then performed to determine gene correlations with Pearson’s correlation 
coefficient. The statistical significance of these correlations was determined with the Analysis 
of Variance test (ANOVA). Plots were generated in R using the lattice and ggplot2 packages.  
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3.2.3 RNA-Seq data analysis in R Bioconductor 
Gene-level transcription estimates in RPKM values (Reads Per Kilobase of exon model per 
Million mapped reads) were obtained for each RNA-Seq dataset. Genes were mapped onto the 
human genome coordinates using UCSC human genome hg19. The data was parsed in R to 
extract the RPKM values for specific genes (e.g. EIF4E, RELA) and generate correlations. 
Phenotypical features of the samples in the TCGA dataset included information regarding the 
clinical prognosis for each AML sample as well as overall survival. Kaplan-Meier overall 
survival analysis was performed using the Survival R package and log-rank p values were 
calculated using the Mantel-Cox test. Heat maps were plotted with the gplots R package.  
 
3.2.4 ChIP-Seq quality control and data analysis with IGV, MEME, TFSEARCH, R 
Bioconductor and Panther 
ENCODE has implemented several statistical and quality control algorithms to ensure 
reporting of statistically significant enrichments with high consistency and reproducibility. An 
overview of the NF-κB RelA ChIP-Seq experiments is shown in Supplementary Figure 2. A 
numeric integrated quality flag was curated to reflect the quality and reliability of the 
experiments; a value of -1 is indicative of poor quality scores, whereas values of 0 and 1 are 
indicative of moderate and high/satisfactory qualities respectively. Furthermore, functional 
genomics experiments (ChIP-Seq) often produce artifact signals in particular regions of the 
genome (e.g. repeats). These regions are referred to as blacklisted regions; a percentage score 
of the blacklisted reads is usually reported. A summary of the quality control flag and blacklist 
percentages for all the experimental datasets described.  
 
NarrowPeak files were downloaded from ENCODE and represent statistically significant 
enriched peaks calculated by the SPP peak caller, these were analyzed using several dedicated 
tools. The files were loaded in the integrative genomics viewer (IGV)36 to visualize the 
transcription factor enrichment across the genome. The DNA sequence files corresponding to 
enriched genomic regions were obtained using the custom tracks tool from the UCSC Genome 
Browser (http://genome.ucsc.edu). Global NF-κB motif enrichment was performed with 
MEME-ChIP (http://meme.nbcr.net/meme/cgi-bin/meme-chip.cgi)37. Enriched NF-κB peaks 
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lacking a consensus NF-κB binding motif were searched with TFSEARCH38 for putative 
transcription factors that could tether NF-κB to those regions. In an attempt to discover new 
NF-κB target genes with a regulation mode similar to that of EIF4E, the NF-κB enriched DNA 
sequences were parsed in the R programming language to determine genomic regions 
containing the NF-κB binding sites that have been identified and validated in the EIF4E 
promoter4. The identified regions were annotated using the ChIPpeakAnno39 and org.Hs.eg.db 
(human genome hg19) packages. Functional gene annotation was then performed with 
Panther40. The median expression for these genes in different AML prognosis groups was 
determined from the TCGA RNA-Seq dataset.  Statistical significance for the differences in 
median gene expression between favorable and poor AML prognosis groups was determined 
by the non-parametric Wilcoxon-Whitney-Mann test. False discovery rate (FDR) was 
determined according to Benjamini and Hochberg.  
3.3 Results 
3.3.1 EIF4E and NF-κB RELA mRNA expression levels follow a positive Pearson 
correlation in AML 
Our initial findings suggested that EIF4E is an NF-­‐κB	   inducible	   gene4.	  Here, we aimed at 
extending our original observations and explore a correlation between EIF4E and RELA 
mRNA levels in AML primary specimen from a large sample population. Accordingly, a large 
microarray gene expression dataset was analyzed and the Pearson correlation was determined. 
The data shown in Figure 1 suggests a statistically significant (p < 0.01) positive correlation (r 
= 0.172) between EIF4E and RELA mRNA levels from 283 AML samples32. This finding 
suggests that increased RELA mRNA expression in AML is likely linked to upregulated 
EIF4E expression. The converse also holds true, whereby increased  EIF4E expression may be 
linked to elevated RELA expression. 
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Figure 1. EIF4E and NF-κB RELA mRNA expression levels are positively correlated in 
an AML microarray gene expression study.  Correlation plots between EIF4E and RELA 
mRNA levels are shown from a microarray AML dataset [Walter MJ et al. 2009]. Each open 
circle represents a patient. Gene expression is denoted as log2 expression for microarray data 
The Pearson correlation coefficient is represented as (r). Statistical significance was 
determined with ANOVA (analysis of variance).  
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3.3.2 EIF4E and RELA mRNA expression levels predict poor overall survival outcomes 
The prognostic classification of AML links cytogenetic anomalies and molecular aberrations 
to predict patient outcome and response to therapy8. Since EIF4E and RELA mRNA 
expressions are upregulated in AML, we sought to determine whether high levels of EIF4E 
and RELA are indicative of poor patient prognosis. Accordingly, we analyzed a TCGA RNA-
Seq dataset from 167 AML patients with relevant overall survival data. These patients were 
classified into the three clinical cytogenetic prognosis groups (Favorable, Intermediate, poor).  
 
In order to determine whether this elevated expression correlates with worse patient survival 
outcomes, Kaplan-Meier overall survival was determined for these AML patients stratified 
into two groups: EIF4E and RELA high (sample size = 10) versus EIF4E and RELA low 
(sample size = 53). EIF4E and RELA high samples reflect RPKM values that are higher than 
the lowest median expression for those genes observed in the clinically favorable AML 
samples (EIF4E RPKM > 3 and RELA RPKM > 5). The survival plot shown in Figure 2 
represents the overall survival probability as a function of time (days) and indicates that 
elevated EIF4E and RELA mRNA levels predict a significantly (log-rank p < 0.05) worse 
trend of patient survival outcomes than low levels of these respective oncogenes. Furthermore, 
survival data from patients with near threshold RPKM values as well as RPKM high values 
for either EIF4E or RELA (sample size = 104 labeled as “Other”) revealed a survival outcome 
similar to that of the EIF4E and RELA low group (Supplementary Figure 1B). Taken together, 
these findings suggest that elevation of both EIF4E and RELA mRNA expressions predict 
inferior survival outcomes. Accordingly, elevated EIF4E and RELA mRNA levels may serve 
as prognostic markers in AML.  
 
3.3.3 The RelA and p50 consensus binding sites are significantly enriched in the ENCODE 
NFkB ChIP-Seq datasets from B-lymphoblast cells 
In an attempt to provide an in depth understanding of EIF4E’s complex transcriptional control, 
we analyzed ChIP-Seq datasets from ENCODE.  RelA (p65) ChIP-Seq datasets were available 
from 10 B-lymphoblast cell lines (immature B-cells) stimulated with TNF-α, a known NF-κB 
activator41 (Supplementary Table 1). Initial characterization of these datasets was conducted to 
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ensure quality and reliability of the drawn conclusions. A summary of the quality control 
metrics is shown in Supplementary Table 2; the data is indicative of high and reliable quality 
with less than 1% of the enriched sequence reads in blacklist regions. Analysis for NF-κB 
motif enrichment in these datasets with MEME-ChIP indicates a statistical significant 
enrichment of the RelA and NF-κB1 (p50) consensus motifs (Figure 3A, 3B and 
Supplementary Table 3). RelA has been shown to homodimerize or heterodimerize with NF-
κB142; this is reflected in the co-enrichment of the binding motifs for both RelA and p50 in the 
ENCODE NF-κB ChIP-Seq datasets. The observed sequence similarity in the reported 
consensus sites can be attributed to a conserved DNA binding domain (Rel homology) in NF-
κB proteins7.  
 
Furthermore, since RelA protein has been demonstrated to form homodimers as well as 
heterodimers with all other NF-κB species, it is quite striking that the predominant species that 
are possibly formed are RelA-RelA homodimers and RelA-p50 heterodimers. This may 
suggest a lineage dependent observation as the samples are of the immature B-cell lineage.  
 
Additionally, RelA is enriched across the entire genome (Figure 3C) suggesting a genome 
wide regulatory mode for NF-κB. Furthermore, the enrichment pattern is consistent across the 
10 datasets suggesting robust and reproducible immunoprecipitations as well as peak calling. 
Taken together, these datasets can be used in the comprehensive analysis for EIF4E 
transcriptional regulation.   
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Figure 2. Elevated EIF4E and NF-κB RELA mRNAs predict worse survival outcomes in 
AML. Kaplan–Meier plots of overall survival from AML patients stratified by EIF4E and 
RELA levels. EIF4E and RELA high samples reflect RPKM values that are higher than the 
lowest median expression for those genes observed in the clinically favorable AML samples 
(EIF4E high RPKM > 3 and RELA high RPKM > 5). Each mark on the survival curve 
represents a censored event where the patient is still alive at the end of the study. Mantel–Cox 
test was performed to calculate log-rank P values. Data source: AML TCGA study.  
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Figure 3. The RelA and p50 consensus binding sites are significantly enriched in the 
ENCODE NF-κB ChIP-Seq datasets suggesting the formation of RelA and p50 
complexes in the regulatory regions of target genes. Sequence logo representation of RelA 
(A) and NF-κB1 (p50) (B) consensus motifs enriched in the reported ENCODE NF-κB ChIP-
Seq datasets were generated with the MEME-ChIP tool. These are position-specific 
probability matrices that specify the probability of each possible nucleotide, in bits, appearing 
at each possible position in an occurrence of the motif. (C) Graphical representation with IGV 
of statistically significant RelA peaks across the genome from 10 B-lymphoblast cell lines 
reflects a consistent genome wide enrichment of RelA across all samples in this dataset.  
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3.3.4 RelA (p65) is enriched in the EIF4E promoter and intron and could be recruited 
indirectly to the EIF4E locus  
We have previously identified and validated four κB binding sites in the EIF4E promoter 
(Figure 4A and 4B) that recruit NF-κB factors in a lineage dependent fashion. In mature B-
cells, κB3/4 are accessible to NF-κB proteins but not κB1/2; on the other hand, all sites are 
accessible to NF-κB factors in myeloid cell lines and primary specimens4. Interestingly, we 
have also identified two conserved κB intronic elements that can bind NF-κB complexes in 
vitro (unpublished findings, Chapter 4); however, the accessibility of these elements and their 
capacity to bind NF-κB proteins in vivo was not investigated. Given the wealth of data that 
could be mined from the ChIP-Seq datasets, we sought to monitor the enrichment pattern of 
RelA in the EIF4E promoter and intron. In the investigated datasets, RelA peaks were 
significantly enriched in the EIF4E promoter and intron in 4 out of the 10 datasets (Figure 
4C). As a control, we examined RelA enrichment in other known NF-κB target genes BCL243 
and NFκBIA44 (IκB- α) and the results show enrichment with RelA peaks in all of the 10 
datasets (Supplementary Figure 3A). These controls further attest to the quality of the 
examined ChIP-Seq datasets as these genes represent validated NF-κB targets. It is important 
to note that no RelA peaks were present in the CCND1 (CyclinD1) promoter45, whereas RelA 
peaks were present in 3 and 4 datasets for the NF-κB targets PIM146 and MYC47 respectively. 
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Figure 4. NF-κB (RelA) is enriched in the EIF4E promoter and first intron. (A) 
Schematic representation of the EIF4E regulatory locus. Promoter and intronic κB sites are 
indicated in green and orange respectively. (B) The distribution, sequence and validation 
methods for the different κB elements in the EIF4E promoter and intron are presented. (C) 
NF-κB RelA enrichment peaks across the EIF4E promoter and intron were generated with 
IGV from four B-lymphoblast datasets and reveal RelA enrichment in the EIF4E promoter 
and intron. The position of these peaks with respect to the EIF4E transcriptional start site is 
shown in green. Previously validated κB sites are referenced for each peak in blue lettering.  
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RelA peaks in the EIF4E regulatory region were localized to the promoter and the first intron 
(Figure 4C and Supplementary Sequences). In the GM15510 and GM18951 datasets, the RelA 
peaks contained the two intronic elements, which we previously validated with gel shift 
experiments. In the GM12878 dataset, the RelA peak contained two NF-κB promoter sites 1 
and 2, which we have previously validated with gel shift and ChIP experiments. Importantly, 
no additional NF-κB binding sites were identified in these datasets. These findings suggest 
that the intronic κB elements are accessible in cell lines; however, further investigation is 
required to elucidate whether these elements are functional in promoting NF-κB-dependent 
transcriptional control of EIF4E. Furthermore, κB1/2 elements enrichment in this immature B-
cell backbone suggests that these elements might be accessible during B-cell development but 
not in mature B-lymphocytes as previously determined from ChIP experiments in mature 
BJAB cells4. 
 
Interestingly, in the GM12891 cell line, RelA peaks were present in both the EIF4E promoter 
and first intron; however, sequence analysis revealed no NF-κB binding sites. Given that the 
promoter peak was shifted by 31 base pairs from the κB-containing peak in GM12878, it is 
most likely the product of peak calling stringency; however, the intronic peak in GM12891 is 
an independent peak that suggests an indirect RelA recruitment to the EIF4E intron through 
other transcription factors and/or complexes. Accordingly, we analyzed the sequence 
underlying this RelA peak in the GM12891 cell line using TFSEARCH and identified 3 
binding sites for proteins known to interact with RelA: Cdx, SP1 and STAT. These factors 
have been shown to interact with RelA and potentiate or alleviate its transcriptional power. A 
brief overview of these factors is presented below.  
 
a) Cdx is a caudal type homeobox factor that has been identified as a colonic tumor 
suppressor. It was shown to interact with RelA/p50 and impede the complex’s 
transcriptional activity48.  
b) SP1 is a zinc finger transcription factor involved in various cellular processes. It has 
been shown to interact with various NF-κB factors including RelA to promote 
leukemogenesis49. 
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c) STAT is a signal transducer and activator of transcription with diverse functions. 
STAT proteins mediate hematopoiesis and hematopoietic functions50, it interacts with 
RelA to enhance51 (STAT3) or suppress52 (STAT1) its activities.  
 
Currently, there is no evidence supporting a role for these factors in the control of protein 
synthesis. Given the ability of these factors to interact with and modulate RelA activity, it 
would be plausible to consider an indirect RelA recruitment to the EIF4E regulatory regions 
through tethering with one or more of these factors. Further experiments are needed to 
investigate this hypothesis.  
 
3.3.5 In silico prediction of 8 new putative NF-κB target genes that may be regulated with a 
pattern similar to EIF4E in poor prognosis AML 
My research on the transcriptional regulation of EIF4E in AML suggests that the selective 
overexpression of EIF4E across different AML groups may be the product of selective NF-κB 
recognition of its binding sites in the EIF4E promoter4. This intriguing notion sparkled an 
interest for new NF-κB target gene prediction that may be regulated in a manner similar to that 
of EIF4E through the same κB elements. Accordingly, we screened the NF-κB ChIP-Seq 
datasets for genes with NF-κB enrichment in promoter and/or intronic regions containing any 
of the previously validated κB binding sites present in the EIF4E regulatory regions (Figure 
4A and 4B). 47 genes were predicted as putative targets with NF-κB RelA enrichment in their 
regulatory regions containing one or more of the previously identified κB sites in the EIF4E 
promoter and intron (Supplementary Table 4); these regions are evolutionary conserved in 
monkey and chimpanzee. Interestingly, one of these genes, IL2RA, has been previously 
validated as an NF-κB target53. The biological process annotation was performed using the 
Panther database40 (Figure 5A and Supplementary Table 5) which suggests that these new 
candidate genes are part of diverse cellular processes most of which are dysregulated in 
cancer.  
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Figure 5. In silico prediction of new putative NF-κB target genes that are upregulated in 
poor prognosis AML specimens. (A) New genes with NF- κB RelA enrichment at regulatory 
regions containing one or more EIF4E κB elements. These sequences and their respective 
position in the identified target genes are evolutionary conserved in monkey and chimpanzee. 
Functional annotation of 46 new putative NF-κB targets was performed with Panther and is 
graphically presented as frequency of genes associated with a biological process. (B) Heat 
map depicting the median expression signatures of 9 predicted targets across AML risk 
groups. The color intensity is proportional to the scaled gene expression values with red as 
high and green as low. Non-parametric Wilcoxon-Whitney-Mann test was used to analyze the 
differences between groups and the false discovery rate (FDR) was determined according to 
Benjamini and Hochberg. The biological function for these targets is also shown.  
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Next, we sought to determine whether any of these newly identified genes is dysregulated in 
AML in a manner similar to that of EIF4E. Accordingly, we analyzed the expression pattern 
of these candidate genes in the TCGA RNA-Seq14. Only genes with significant median 
expression pattern similar to EIF4E that is higher in the poor prognosis group were selected 
and are shown in the heat map in Figure 5B with the adjusted p value and biological function. 
 
Nine genes presented an expression pattern that is similar to EIF4E as determined from 167 
AML specimens. This pattern depicts a poor prognosis high and favorable prognosis low 
median expression; these genes were: CYTH4, WDR33, SNX32, RARG, PPP1R15B, TRAP1, 
CHD9, PLXNA1 and IL2RA. However, these findings are of preliminary nature and further 
studies are required to investigate the functional relevance of these new targets in AML and 
whether their transcriptional regulation is NF-κB dependent.  
 
3.3.6 In silico prediction of 6 new putative EIF4E transcriptional regulators 
The EIF4E promoter contains an abundance of transcription factor binding sites including 
Myc, NF-κB, AP1, PU.1, SP1, GATA, OCT1, CREB, PAX5, E2F, STAT5, NFATC1 and 
many others. These have been predicted through MatInspector analysis23 and would suggest a 
complex mode of lineage-dependent and/or stimulus-dependent transcriptional regulation. 
However, with a predominant Myc-centric view, not much has been done to investigate the 
requirement of these putative regulatory sites. Accordingly, we analyzed ChIP-Seq datasets 
for a number of these factors in the available hematopoietic cell lines from ENCODE. These 
included the B-lymphoblast cell lines: GM12878, GM12891 and GM12892, as well as the 
chronic myelogenous leukemia (CML) cell line K562. The relevant transcription factor peaks 
across the EIF4E promoter and intron in the available cell lines are delineated in Figure 6. A 
brief overview of these factors and their enrichment patterns is presented below.  
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Figure 6. In silico prediction of 6 new putative EIF4E transcriptional regulators. 
Graphical representation with IGV of the EIF4E regulatory regions with SP1, STAT5, PU.1, 
PAX5, GATA2 and NFATC1 peaks in lymphoblast (GM12878, GM12891, GM12892) and 
chronic myelogenous leukemia (K562) cell lines.   
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a) PU.1 is a transcription factor important in myeloid and B-lymphoid cell development. 
ChIP-Seq experiments were performed in the GM12878, GM12891 and K562 cell 
lines. In GM12878, PU.1 enrichment peaks were present in the EIF4E promoter 
proximal and distal to the transcription start site. In GM12891, PU.1 enrichment peaks 
were present in the EIF4E promoter and intron. No peaks were detected in the K562 
cell line. 
b) PAX5 is a transcription factor that functions as a B-cell lineage specific activator 
protein expressed during B-cell differentiation. The available experiments were 
conducted in the GM12878, GM12891 and GM12892 lymphoid cell lines. PAX5 
peaks were observed at a distance upstream of the EIF4E promoter in GM12878 and 
GM12891 whereas in the GM12892 cells, the peaks were detected in the promoter and 
intron regions of EIF4E. 
c) The SP1 and STAT factors were discussed in the previous section. The available 
ENCODE data suggests SP1 recruitment to the EIF4E promoter in the GM12878 and 
K562 cell lines. STAT5 peaks were detected in the EIF4E promoter and intron in the 
GM12878 and K562 cell lines respectively.  
d) The GATA zinc finger transcription factors belong to a diverse and conserved family 
of transcriptional regulators involved in cardiac and hematopoietic development. 
GATA1 and GATA2 ChIP-Seq experiments were analyzed in the K562 CML cell line. 
No GATA1 peaks were detected in the EIF4E regulatory regions, whereas GATA2 
peaks were detected in the EIF4E promoter in two different experiments conducted by 
the Snyder and Myers groups. 
e) The NFATC1 transcription factor plays an integral role in modulating inducible gene 
expression during an immune response. An NFATC1 ChIP-Seq experiment was 
analyzed in the GM12878 cell line revealing peaks in the EIF4E promoter.  
 
The aforementioned data predicts 6 new putative EIF4E regulators and supports an intricate, 
dynamic and most importantly a non-nodal regulation of EIF4E. The identified factors are 
important for myeloid or lymphoid (or both) development and functions.  In fact, aberrations 
in these factors have been linked to hematopoietic malignancies. GATA2 and SP1 have been 
linked to myeloid transformation49,54. PAX5 and PU.1 have been linked to B-cell55,56 as well 
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as myeloid leukemias57,58. Accordingly, this data suggests that EIF4E could be regulated by 
these additional transcription factors and would be dysregulated in hematopoietic anomalies 
associated with aberrations in these proteins; however, further work is needed to evaluate this 
hypothesis since there is no current evidence linking any of the aforementioned factors to 
mRNA translation and protein synthesis.  
 
3.4 Discussion 
In this study, we described a positive correlation between EIF4E and RELA mRNA expression 
in AML. In addition, elevated mRNA levels for these genes predict a worse trend for patient 
survival. However, several caveats must be considered, first, these conclusions were drawn 
from experiments that reflect mRNA expression for these oncogenes (microarray) with no data 
regarding protein levels. Second, although elevated RELA expression levels have been linked 
to constitutive NF-κB activity in cancer7, additional experimentation is required to establish 
this activity in the samples tested.  Taken together, these findings offer a new venue for 
research into EIF4E and RELA as poor prognosis markers in AML; however further 
investigation is required. The significance of this association is inherent in the proper planning 
of treatment protocols for patients with high EIF4E and NF-κB by targeting EIF4E with 
Ribavirin16 and NF-κB with current pathway inhibitors19,59.  
 
My previous findings show that NF-κB proteins are directly recruited to conserved κB 
elements in the EIF4E promoter with lineage preference to regulate EIF4E gene expression4. 
In an attempt to further dissect the transcriptional regulation of EIF4E, we analyzed ENCODE 
NF-κB ChIP-Seq data obtained from 10 B-lymphoblast cell lines. NF-κB (Rel A) peaks were 
detected in 4/10 samples engaging 2 promoter (κB1/2) and 2 intronic elements. However, it is 
important to keep in mind that peak detection is affected by several factors including the 
stringency of the peak detection algorithm31. Furthermore, the cell lines under study were 
EBV+, which imparts constitutive NF-κB activity in those samples. These facts together with 
the chosen treatment conditions (TNF-α) present caveats that may underlie the observed NF-
κB enrichment in only 4/10 cell lines.  
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Interestingly, the NF-κB enrichment in the EIF4E intron suggests that these elements might be 
active in vivo and are potentially functional in driving EIF4E transcriptional control. However, 
it remains intriguing as to what cellular conditions are decisive of NF-κB recruitment to the 
intronic and/or promoter regions; this could be the result of differences in the chromatin status 
at the EIF4E locus which may either hinder or favor NF-κB recruitment to different regions in 
the EIF4E promoter and/or intron. Additionally, NF-κB recruitment to the κB1/2 sites in the 
tested immature B-lymphoblast cell lines may suggest that NF-κB accessibility to these 
elements is selective to B-cell developmental stages since ChIP experiments suggested that 
these sites were not bound by NF-κB proteins in a mature B-cell line4. Furthermore, the results 
obtained with the GM12891 cell line suggest that NF-κB could be recruited to the EIF4E 
locus through other transcriptional regulators (Sp1, STAT, Cdx); additional work is needed to 
validate this observation.   
 
In this study, we provided evidence that EIF4E could be regulated through additional 
transcription factors (e.g. GATA2, SP1, PAX5, PU.1). The data suggests that these factors 
could be recruited to the EIF4E promoter; however further experiments are required to 
examine whether the recruitment of these factors is coupled to EIF4E transcription. As some 
of these modulators are dysregulated in AML and lymphoma, it would be interesting to study 
the effect of those factors on EIF4E regulation in those cancers. Finally, 8 new putative NF-
κB target genes were predicted that are possibly upregulated in poor prognosis AML similar to 
EIF4E and accordingly, maybe considered as risk markers in AML. However, further 
investigation is required to validate these genes. Finally, it would be interesting to investigate 
whether any of these targets are also regulated by EIF4E, given that EIF4E has been shown to 
amplify the “NF-κB effect” by enhancing the mRNA export and/or translation of NF-κB 
targets (e.g. CCND1, PIM1, MYC)4,60. 
 
3.5 Conclusion 
In conclusion, this study presents putative insights into the association of EIF4E and RELA 
expression in AML poor risk group as well as the complexity of EIF4E’s transcriptional 
control. The analysis presented in this chapter may inspire new research focused on targeting 
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AML poor prognosis patients with elevated EIF4E and NF-κB with Ribavirin and NF-κB 
inhibitors. Additional research perspectives include understanding EIF4E’s transcriptional 
control through new transcription factors as well as investigate an NF-κB dependent 
mechanism of regulation for the newly discovered putative targets in poor prognosis AML that 
were reported in this study.   
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Supplementary Material 
Supplementary Figure1. Intermediate and poor prognosis AML groups predict inferior 
survival outcomes. Kaplan–Meier plots of overall survival from 167 AML patients stratified 
by clinical risk groups: favorable (n = 33), intermediate (n = 98) and poor (n = 36). Each mark 
on the survival curve represents a censored event where the patient is still alive at the end of 
the study. Mantel–Cox test was performed to calculate log-rank P values. Data source: AML 
TCGA study. 
 
Supplementary Figure2. Overview of the various stages in an NF-κB ChIP-Seq 
experiment. The cells are fixed with formaldehyde to generate a snapshot of the cellular 
chromatin status. The isolated chromatin is than fragmented and immunoprecipitated with an 
NF-κB antibody  (RelA). Each ChIP experiment is performed with at least two biological 
replicates derived from independent cell cultures. Following immunoprecipitation, the purified 
DNA is sequenced with Illumina NextGEN sequencing. The sequenced reads are then mapped 
to a reference genome and only statistically significant signal/background enrichments from 
biological replicates will represent peaks. Peak calling is performed by overlapping 
statistically significant mapped reads over genomic regions. Additional post-filtering 
algorithms are applied for motif discovery and to eliminate artifacts.  
 
Supplementary Figure3. NF-κB (RelA) is enriched in the promoter and intron of two 
validated NF-κB target genes: NFκBIA and BCL2. NF-κB RelA enrichment peaks across 
the NFκBIA (A) and BCL2 (B) promoter and intron were generated with IGV from 10 B-
lymphoblast datasets and reveal RelA enrichment.  
 
Supplementary Table1. An overview of the 10 B-lymphoblast cell lines presented in this 
study.  
 
Supplementary Table2. List of the cell lines and the ChIP-Seq datasets used in this study. 
An integrated quality control flag denotes the reliability of the chosen dataset with poor (-1), 
moderate (0) and high quality (1) metrics. 
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Supplementary Table3. NF-κB RelA and NF-κB1 (p50) motif enrichment in the 
investigated samples are statistically significant. E-Values were calculated with MEME-
ChIP tool and presented for the 10 B-lymphoblast cell lines used in this study.  
 
Supplementary Table4. List of 47 predicted NF-κB target genes containing EIF4E κB 
sites in their promoter and/ or intron.  
 
Supplementary Table5. List of the functional annotation groups and their underlying 
genes as determined by Panther.  
 
Supplementary Sequences. Base pair DNA sequences of the NF-κB RelA peaks identified 
in the EIF4E promoter and intron. Highlighted sequences represent previously validated κB 
sites.   
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Chapter 4: Discussion and Future Perspectives 	  
 
 
 
 
 
 
 
Contribution: All the data presented in this chapter was generated by Fadi Hariri (100%) 
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4.1 EIF4E is a Direct NF-κB Transcriptional Target and Functions as an Amplifier of 
NF-κB Activity 
My work has shown the EIF4E transcript and protein were inducible in an NF-κB-dependent 
manner in a B-cell lymphoma cell line, BJAB, following stimulation with the phorbol ester 
PMA reaching a maximum of 2-fold transcript induction (Chapter 2, Figure 1). Furthermore, 
EIF4E transcript and protein were also inducible in PMA stimulated primary peripheral blood 
mononuclear cells (PBMCs) reaching a max of 4-fold transcript induction (Chapter 2, Figure 
4)1. This observed discrepancy in the intensity of EIF4E induction is inherent in the 
physiologic nature of the used systems. Primary human cells are quiescent with low basal rates 
of gene expression; accordingly, following stimulation with a growth-promoting agent (e.g. 
PMA), these cells proliferate and display a significant amplification in gene expression 
rates2,3. Furthermore, although PMA stimulation in BJAB cells promoted a 2-fold transcript 
induction, it resulted in a 7.2 fold increase in EIF4E protein levels suggesting the possible 
implication of other regulatory mechanisms under these conditions. The higher levels of the 
EIF4E protein are likely a result of an increase in translation efficiency of the EIF4E transcript 
in response to PMA stimulation.  Accordingly, quantitative polysomal loading experiments 
could be performed to evaluate this hypothesis following PMA stimulation in the presence and 
absence of an NF-κB inhibitor to determine whether the observed effects are NF-κB specific.  
 
NF-κB mediated regulation of EIF4E involves components of the canonical pathway as 
determined by transcription factor binding studies (EMSA and ChIP). NF-κB proteins are 
directly recruited to four evolutionary conserved κB sites in the EIF4E promoter (Chapter 2, 
Figure 2).  Although EMSA studies demonstrated the formation of p65/c-Rel containing 
dimers on κB sites in the EIF4E promoter, supershift experiments with a p50 antibody 
revealed a shifted complex as well; however, no specific p50-containing band could be 
discerned (except in KM-H2 lysates in Chapter 2, Figure 5) leading us to believe that p50 may 
not be a core component. Given that EMSA experiments are performed in an in vitro context 
and thus do not take into consideration the chromatin status at the studied loci, it would not be 
unlikely that p50 protein is recruited to the EIF4E promoter. In fact, both RelA (p65) and c-
Rel are known to heterodimerize with p50. ChIP experiments performed with an NF-κB1 
(p50) antibody would be conclusive in determining whether this subunit is recruited to the 
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EIF4E promoter in response to a growth-promoting stimulus (e.g. PMA). Furthermore, our 
ChIP experiments demonstrated that RelA (p65) fold enrichment is 2.5 and 5 times more than 
c-Rel at the κB3 and κB4 sites respectively in the EIF4E promoter. This observation may 
likely be due to the immunoprecipitation efficiency of the antibodies used. It is important to 
note that the selectivity of our RelA antibody was confirmed through western blot experiments 
using total protein lysates from RelA null fibroblasts (Figure 3D). Thus our findings from 
ChIP experiments are reliable and specific.  Finally, gene silencing studies could be performed 
to determine whether RelA (p65) recruitment to the κB sites was dependent or not on its 
ability to form a heterodimer with cRel or p50. Such experiments would involve knockdown 
of the p50 and c-Rel NF-κB subunits followed by ChIP experiments performed with a RelA 
(p65) antibody in response to PMA stimulation.  
 
Interestingly, the recruitment of NF-κB proteins to these elements is lineage dependent. In 
BJAB cells reflecting a mature B-cell lineage, NF-κB factors are recruited to only κB3 and 
κB4 elements (Chapter 2, Figure 3) and not κB1 and κB2. On the other hand, NF-κB factors 
are recruited to all κB sites in the EIF4E promoter in the myeloid cell lines THP1 and KG1a 
(Chapter 2, Figure 6)1. Furthermore, the level of B-cell maturity may alter the recruitment 
patterns of NF-κB factors to κB sites. In fact, RelA ChIP-Seq data from ENCODE revealed 
NF-κB enrichment in 4/10 B-lymphoblast samples at regions containing κB1 and κB2 sites 
(Chapter 3, Figure 4C). Taken together, these data suggest that NF-κB accessibility to these 
elements in a B-cell lineage is also dependent on B-cell developmental stages.  
 
Analysis of the EIF4E locus with MatInspector4 and TFSearch5 identified two additional 
evolutionary conserved NF-κB binding sites in the EIF4E intron (Chapter 3, Figure 4A). 
These elements were validated to bind NF-κB canonical proteins using in vitro gel shift assays 
(Figure 1). Furthermore, RelA ChIP-Seq data from ENCODE revealed NF-κB enrichment in 
intronic regions containing the identified sites (Chapter 3, Figure 4C). Interestingly, the NF-
κB enrichment in the EIF4E intron suggests that these elements could be functional in driving 
EIF4E transcriptional control. The physiologic significance of these intronic regions remains a 
mystery. It would of interest to study the regulatory effects that these elements impart in 
response to various stimuli and in malignant tissues to further our understanding of the 
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complex mechanisms governing EIF4E transcriptional control. Importantly, NF-κB dependent 
regulation of target genes through intronic binding sites is not uncommon. In fact, NF-κB 
transcription factors have been shown to regulate the immunoglobulin κ-light chain6 as well as 
the FOS gene7 through direct recruitment to intronic elements. Finally, ChIP-Seq data analysis 
from ENCODE suggests that RelA (p65) could be indirectly recruited to the EIF4E promoter 
through Sp1, STAT or Cdx; however, further investigation is needed to validate this 
observation. 
 
Furthermore, it would be interesting to determine the importance of each κB site (promoter 
and intron) in the transcriptional regulation of EIF4E and whether these elements function 
cooperatively under the investigated context. In fact, we have performed luciferase reporter 
assays (LRA) in HEK293 cells co-transfected with a plasmid harboring the human EIF4E 
promoter containing the identified κB elements together with plasmids carrying the different 
NF-κB transcription factors (e.g. RelA, c-Rel). Our findings revealed that the EIF4E reporter 
activity was upregulated following the introduction of RelA (p65) and c-Rel; however, this 
activity was diminished but not completely abrogated when all elements were mutated. Since 
only a fragment of the EIF4E promoter (~1KB) was analyzed, it is not truly a reflective 
template of the cellular context and thus LRAs do not constitute the ideal experiments to 
address this question. A better-suited alternative would involve the use of the RNA-guided 
Cas9 nuclease from the microbial clustered regularly interspaced short palindromic repeats 
system (CRIPSR) for genome editing8. Briefly, two guide RNAs that are complementary to 
regions flanking each κB binding site in the EIF4E regulatory region would be introduced 
together with a Cas9n nickase enzyme into the cell line of choice (e.g BJAB); this strategy 
would allow the deletion of the each κB element at a time (can also be multiplexed). Edited 
cells would then be stimulated (e.g. PMA) followed by the analysis of EIF4E gene expression 
as well as ChIP to evaluate the recruitment of NF-κB factors to the EIF4E regulatory regions. 
These experiments would highlight the requirement of each individual element in the 
regulation of EIF4E expression.  
 
Finally, in addition to its role in EIF4E transcriptional regulation, NF-κB proteins can also 
modulate EIF4E activity indirectly by altering its subcellular localization9. Moreover, several 
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NF-κB target genes are in fact EIF4E mRNA export and/or translation targets (e.g. MYC and 
CCND1)10-12 suggesting that EIF4E may act as an amplifier of NF-κB activity to drive 
proliferative gene expression (Figure 2). EIF4E was also shown to enhance translation of the 
Nfkbi gene encoding for the NF-κB inhibitor IκB-α13, which is also an NF-κB target gene14. 
This NF-κB/EIF4E feedback permits a rapid proliferative response concomitant with a rapid 
shutdown upon signal termination by upregulating the NF-κB inhibitor IκB-α. Furthermore, 
the cyclin dependent kinase inhibitor p19ARF has been shown to bind the EIF4E promoter 
and repress transactivation15; p19ARF is in turn inactivated through NF-κB16. Given the pro-
proliferative advantages conferred by EIF4E, these observations suggest a role for NF-κB in 
combating senescence via the alleviation of p19ARF dependent inhibition of EIF4E 
transcription. Collectively, these findings highlight a nexus between transcriptional and post-
transcriptional gene expression networks to modulate cell proliferation that could be targeted 
in malignant tissue.  
 
4.2 NF-κB as a Complex Regulator of EIF4E expression: Beyond Transcriptional 
Control 
The coordinated regulation of EIF4E expression goes beyond the conventional transcriptional 
control model. In particular, the RNA regulon model emphasizes the role of 
ribonucleoprotein-driven regulation of transcripts through modulating transcript stability, 
export and/or translational efficiency17. For instance, elevated levels of the RNA binding 
protein HuR has been shown to enhance EIF4E transcript stability in the head and neck 
carcinoma FaDu cells but not in Detroit-551 cells with low HuR18. This suggests that different 
cell lineages may differentially express EIF4E through a mechanism that is not 
transcriptionally dependent and would involve post-transcriptional events.  
 
Throughout the course of my PhD studies, I investigated the effect of several NF-κB 
activating agents on EIF4E expression including the tumor necrosis factor TNF-α and 
immunoglobulin M (IgM). Two systems were used, mouse embryonic fibroblasts (MEFs) with 
a genetic knockout for RelA (p65) as well as BJAB cells. Only the EIF4E protein was 
upregulated in wildype MEFs but not in the p65 -/- cells in response to TNF-α treatment. 
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Similarly, in BJAB cells, EIF4E protein was upregulated following TNF-α and IgM 
stimulation with minor changes in mRNA expression levels (Figure 3).  
 
These findings suggest an NF-κB dependent post-transcriptional and/or post-translational 
control of EIF4E expression; however, further experiments are needed to investigate this 
hypothesis. Accordingly, cells would be treated with ActinomycinD or cycloheximide to block 
gene transcription19 and mRNA translation20 respectively. Cells will then be treated with NF-
κB activating agents and total mRNA and protein would be extracted. EIF4E transcript and 
protein would then be assayed with quantitative realtime PCR and western blot respectively. 
The effect of NF-κB activating stimuli on EIF4E mRNA and protein stability would then be 
determined.  
 
These preliminary findings constitute lead points for future investigation. Establishing an NF-
κB role in the post-transcriptional and/ or post-translational control of eI4FE would suggest 
that NF-κB is a complex modulator of EIF4E expression that functions at all levels of genetic 
control to maintain elevated EIF4E levels under proliferative conditions.  
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Figure 1. Two intronic κB elements are bound by NF-κB complexes. Electrophoretic 
mobility shift assay (EMSA) of nuclear extracts prepared from PMA-stimulated BJAB cells 
(90 min) using probes corresponding to the intronic κB sites. Supershift analysis using 
antibodies against p65, p50, cRel and immunoglobulin G (IgG) control as well as competition 
with consensus cold probe (CP) are indicated. Protein/DNA complexes are indicated by 
arrows. Supershifted complexes are indicated by an asterisk. These binding studies were 
performed at least three times using nuclear extracts prepared from cell lines and primary 
specimens.   
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Figure 2. EIF4E is a downstream NF-κB target that acts as an amplifier of NF-κB 
activity to drive proliferative gene expression. EIF4E is upregulated in response to 
proliferative stimuli. EIF4E export and/or translation targets are also NF-κB transcription 
targets, thus EIF4E functions to enhance the NF-κB response. EIF4E was also shown to 
enhance translation of the IκB-α; this feedback allows a rapid proliferative response followed 
by a rapid shutdown upon signal termination by upregulating the NF-κB inhibitor IκB-α. 
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Figure 3. Regulation of EIF4E gene expression through NF-κB may involve post-
transcriptional or post-translational events. (A, B) Minimal changes in EIF4E mRNA 
following IgM and TNF-α stimulation in BJAB cells. (C) EIF4E protein is upregulated in 
response to IgM and TNF-α in BJAB cells. (D) EIF4E protein is upregulated in wild type 
mouse embryonic fibroblasts (MEFs) but not in the NF-κB p65 -/- cells following TNF-α 
treatment. C refers to control untreated cells. IgM and TNF-α were performed twice.  
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4.3 EIF4E gene regulation is multifaceted and involves several transcription factors 
The EIF4E promoter harbors a plethora of transcription factor binding sites including AP1, 
PU.1, SP1, GATA, OCT1, CREB, PAX5, E2F, STAT5, NFATC1 and many others21. 
Recently, C/EBP has also been shown to regulate EIF4E transcription22 consistent with the 
fact that EIF4E transcriptional control is not solely dependent on Myc. Analysis of ENCODE 
ChIP-Seq datasets to discern the genomic binding patterns of the aforementioned transcription 
factors was performed. Accordingly, six new regulators were predicted to be recruited to the 
EIF4E regulatory regions. These factors are PU.1, PAX5, SP1, STAT, GATA2 and NFATC1 
(Chapter 3, Figure 6). These factors are integral to myeloid and lymphoid development and 
functions whereby aberrations in these proteins have been linked to hematopoietic anomalies. 
GATA2 and SP1 were implicated in myeloid transformation23,24, whereas PAX5 and PU.1 
have been implicated in B-cell25,26 as well as myeloid leukemias27,28.  
 
Interestingly, the phorbol ester PMA regulates the activity of STAT29, GATA30, NFAT31, 
PAX32 and PU.133. BJAB cells co-treated with an NF-κB inhibitor failed to upregulate EIF4E 
in response to PMA (Chapter 2, Figure 1) suggesting that the observed EIF4E upregulation 
through PMA is strictly dependent on NF-κB and does not involve these factors; however, 
these proteins may still function as putative regulators of EIF4E under different conditions an 
in distinct cell contexts.  
 
Investigating EIF4E transcriptional control through these factors constitutes future 
perspectives for follow-up studies further reasserting the complex and dynamic regulation of 
EIF4E. Accordingly, the expression levels as well as activity of these transcription factors will 
be evaluated in normal and malignant hematopoietic cells with western blot and gel shift 
experiments respectively. EIF4E expression would be evaluated following treatments with 
activating agents, as well as gain or loss of function in each of the aforementioned factors. The 
in vivo recruitment of these proteins to the EIF4E promoter would also be monitored with 
ChIP in normal and malignant cells. These studies would implicate the identified putative 
regulators in EIF4E transcriptional control.  
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4.4 Selective Recruitment of NF-κB Proteins to the EIF4E Promoter Underlies its 
Differential Regulation in AML 
My gel shift and chromatin immunoprecipitation (ChIP) experiments performed in AML 
primary specimens have shown that the NF-κB factor RelA (p65) selectively binds to three 
elements in the EIF4E promoter in M4/M4 primary AML specimens but not in M2 AML or 
normal control (Chapter 2, Figure 7)1. Given that EIF4E is an NF-κB target, this novel finding 
was the first to explain the underlying preferential regulation of EIF4E in AML. 
 
Recent research has identified nuclear NF-κB proteins known as non-Rel factors that 
selectively regulate NF-κB affinity to binding sites as well as its activity across gene 
promoters [Reviewed in Chapter 1.8.3]. The mechanism through which these non-Rel factors 
regulate NF-κB activity involves the crosstalk with other transcription factors, chromatin 
remodeling as well as NF-κB turnover. This body of research suggests that the selective 
recruitment of NF-κB complexes to the EIF4E promoter across different AML subtypes1 is 
possibly due to nuclear non-Rel protein components.  
 
Investigating the selective recruitment of NF-κB complexes to the EIF4E promoter through 
non-Rel nuclear proteins constitutes a future perspective for follow-up studies to delineate the 
full mechanism underlying the differential EIF4E regulation in AML subtypes. In order to 
identify these protein components underlying the differential NF-κB activity on the EIF4E 
promoter in AML, biotinylated EIF4E promoter fragments corresponding to the validated NF-
κB elements would be prepared. These will be immobilized on streptavidin coated magnetic 
beads 34. Nuclear extracts from the different AML subtypes (M1, M2, M4 and M5) as well as 
normal controls will then be prepared; these extracts will be incubated with the immobilized 
EIF4E promoter elements. The proteins bound to the immobilized fragments will be recovered 
and subsequently analyzed by mass spectrometry to determine their composite members. ChIP 
and gel shift EMSA experiments will also be carried out to validate the identified proteins on 
the EIF4E promoter in vivo and in vitro respectively. These studies would thus elucidate non-
Rel protein complexes that are recruited the κB sites in the EIF4E promoter. Furthermore, 
genetic gain and loss of function experiments performed with the identified proteins would 
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highlight the role of these factors in regulating EIF4E expression concomitantly with NF-κB 
in myeloid cells.  
 
The observed selective recognition of NF-κB complexes on the κB sites in the EIF4E 
promoter sparkled an interest in new NF-κB target gene prediction that may be regulated in a 
manner similar to that of EIF4E in AML through the same unique κB elements. Accordingly, 
NF-κB ChIP-Seq datasets were analyzed to retrieve genes with NF-κB enrichment on one or 
more κB sites that have been previously validated in the EIF4E promoter. 47 genes implicated 
in diverse biological processes were predicted as putative NF-κB targets (Chapter 3, Figure 
5A).  This finding offers a new directive for future investigations involving NF-κB research to 
validate new genes that may be selectively regulated through their unique κB sites. In fact, 8 
of the identified genes show an expression signature similar to that of EIF4E in adverse 
prognosis AML samples suggesting that they may also be differentially regulated in AML 
(Chapter 3, Figure 5B). The validation of these genes as NF-κB targets that are differentially 
regulated in AML would serve, together with EIF4E, as prognostic risk gene signature for 
poor prognosis AML.  
4.5 Elevated NF-κB (RELA) and EIF4E levels in AML Serve as Poor Risk Markers and 
Suggest a New approach of Targeting to Inhibit EIF4E Expression 
NF-κB is constitutively activated in a plethora of cancers and this activity is largely due to 
gene amplification, mutations as well as rearrangements in elements of the pathway35. In 
AML, constitutive NF-κB activity is underlined by an aberration in the signaling cascade as 
well as an upregulation of RELA (p65) due to amplification in chromosome 1136,37. Analysis 
of a TCGA RNA-Seq dataset from AML patients suggested a correlation between elevated 
RELA and EIF4E expression in poor risk patient specimens (Chapter 3, Figure 2).  
Furthermore, elevated RELA and EIF4E mRNA levels predict worse survival outcomes in 
AML. These findings suggest that both EIF4E and RELA may serve as prognostic markers in 
AML. EIF4E targeting in AML has been successfully achieved with ribavirin38,39.  
 
My findings regarding NF-κB dependent EIF4E regulation in AML suggest a clinical utility in 
controlling the transcription of EIF4E with the use of NF-κB inhibitors, in addition to directly 
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inhibiting EIF4E activity with ribavirin. The most extensively used NF-κB targeting approach 
relies on blocking its activation at the level of nuclear entry. This strategy employed the use of 
IκB kinase (IKK) as well as proteasomal inhibitors and has been shown successful in some 
contexts. For instance, targeting NF-κB in acute myeloid leukemia (AML) using proteasomal 
inhibitors have shown to inhibit proliferation in CD34+ populations37. However, constitutive 
NF-κB activity is contributed for by multiple factors; the efficacy of these pathway inhibitors 
is largely determined by the genomic aberrations that resulted in an amplified NF-κB activity.  
 
We have experienced this drawback with NF-κB targeting in several M4/M5 AML primary 
specimen as well as an M5 AML cell line, Thp1 in an attempt to block EIF4E transcription in 
the tested samples. However, only two samples out of 6 M4/M5 AML primary specimens and 
the M5 AML cell line responded to an NF-κB inhibitor, Bay 11-7082 that targets IκB kinase, 
despite the fact that the samples tested harbored constitutive NF-κB activity (Figure 4).  
 
These findings highlight the importance of specific targeting of NF-κB transcription factors to 
circumvent this limitation. The identification of NF-κB small molecule inhibitors represents a 
future directive for NF-κB research that would allow for specific targeting of NF-κB 
transcription factors in a multitude of cancers where constitutive activity is endowed by more 
than one aberration in the pathway. Accordingly, an in silico screening approach combined 
with NMR to identify inhibitors of the DNA binding domains of NF-κB proteins p65, p50 and 
c-Rel would be followed. In silico screening approaches have been effective in identifying 
small protein inhibitors40,41. Thus the proposed strategy presents an effective tool for the 
identification of molecules to use as leads in drug discovery. The identified pharmacological 
candidates would then be investigated in AML primary specimen and a panel of cancer line 
lines for their capacity to inhibit NF-κB DNA binding properties and thus its activity.   
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Figure	   4.	   The	   NF-­‐κB	   inhibitor	   Bay11-­‐7082	   results	   in	   a	   downregulation	   of	   EIF4E	  
expression	  in	  2	  out	  of	  6	  AML	  primary	  specimens.	  EIF4E	  mRNA	  levels	  were	  measured	  by	   quantitative	   realtime	   PCR	   in	   primary	  M4/M5	   AML	   specimens	   treated	   with	   Bay11-­‐7082.	  Transcript	  levels	  were	  normalized	  to	  the	  histone	  2B	  housekeeping	  gene.	  Result	  are	  shown	  as	  fold	  induction	  relative	  to	  untreated	  control	  samples.	  Bay	  refers	  to	  Bay	  11-­‐7082.	  Unt	   refers	   to	  untreated.	   Error	  bars	   represent	   standard	  deviations	   from	   three	   technical	  replicates.	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EIF4E is overexpressed in approximately 30% of cancers including M4 and M5 subtypes of 
acute myeloid leukemia (AML). EIF4E overexpression is correlated with oncogenic 
transformation, metastasis, tumor invasion and poor prognosis. Our group has demonstrated 
clinical improvement in poor prognosis AML patients through the inhibition of EIF4E with 
ribavirin in two clinical studies. This provided the first clinical evidence that EIF4E is a 
therapeutic target. EIF4E is regulated at multiple levels but not much is known about the 
transcriptional regulation of EIF4E. In fact, for the past 16 years, EIF4E transcriptional 
regulation has been thought of as Myc-centric. Expression of the NF-κB super repressor (IκB-
SR) suppresses EIF4E transcript levels in CD34+ M4/M5 AML patient specimens. My 
findings show that EIF4E is a direct transcriptional target of NF-κB. Given that many EIF4E 
export and/or translation targets are also NF-κB targets, EIF4E thus acts as an amplifier of NF-
κB activity.  
 
NF-κB canonical complexes are directly recruited to conserved sites in the EIF4E promoter to 
direct transcription. Furthermore, our findings also suggest that NF-κB proteins can also be 
recruited to intronic elements at the EIF4E locus, although the physiological significance of 
this event remains to be investigated. The requirement of κB sites in the EIF4E promoter is 
dependent on cell lineage and developmental stage. Moreover, our unpublished observations 
suggest an NF-κB mediated post-transcriptional and/or post-translational regulation of EIF4E; 
however, further experimentation is required to validate this hypothesis.  
 
Constitutive NF-κB activity and elevated EIF4E expression levels are observed in a plethora 
of cancers including acute myeloid leukemia. We have shown that selective NF-κB activity on 
the EIF4E promoter represents an underlying factor in determining EIF4E’s differential 
expression in M4/M5 AML subtypes but not in the M1/M2 tested samples. Non-Rel nuclear 
proteins determine the selectivity of NF-κB factors; accordingly, specific non-Rel proteins 
may be dysregulated in M4/M5 AML owing for the observed preferential EIF4E expression. 
Identifying the non-Rel components that dictate NF-κB recruitment and the preferential 
upregulation of EIF4E in AML constitutes a novel future research direction to further our 
understanding of EIF4E dysregulation in AML and the potential means to target it. 
Furthermore, the unique κB sites in the EIF4E promoter are also present and functionally 
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recruit the NF-κB p65 transcription regulator in 47 target genes. These genes present novel 
putative NF-κB targets for prospective validation and investigation. 
 
Finally, elevated EIF4E and NF-κB RELA expression is correlated with adverse AML 
prognosis and predicts a poor survival trend thus may serve as clinical prognostic markers in 
this hematological anomaly. These findings suggest a potential clinical utility in targeting 
EIF4E expression in combination with ribavirin that targets EIF4E activity. Current NF-κB 
pathway inhibitors are not fully capable of inhibiting NF-κB transcription factors and their 
activity as their efficacy is determined by the genomic anomaly associated with the pathway’s 
aberration. My preliminary data in AML primary specimens treated with the NF-κB inhibitor 
Bay11-7082 reinforces this notion. Thus investigating specific inhibitors of NF-κB 
transcription factors can be considered for future studies providing a more precise approach to 
target this pathway in cancer.  
 
This study was the first to explore the mechanistic link between NF-κB and EIF4E activity. 
Understanding this level of regulation within the context of patient specimens is important for 
the development of novel therapeutic strategies, such as combining ribavirin treatment with 
specific NF-κB inhibitors in leukemia patients, in an attempt to more effectively target EIF4E 
and NF-κB networks as well as alleviate symptoms of poor prognosis AML patients to further 
improve the efficacy of patient care. 
.  
 
 
